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Abstract 
Background: The burden of HIV infection is still high in South Africa. However, the use of 
ART has greatly improved treatment outcomes and survival. People infected with HIV and 
receiving ART are therefore living longer but with a likely increase in their cardiometabolic risk. 
Both HIV infection and anti-retroviral drugs have been shown to affect serum lipid levels and 
this may be among the reasons for the increased cardiometabolic risk in these subjects. The aim 
of this study was therefore to characterize the principal determinants of lipid levels in a large 
rural South African population with a high prevalence of HIV infection in which an array of 
factors that possibly modulate serum lipid levels had also been measured.  
Materials and methods: Data for this secondary analysis are drawn from a population-based 
cross-sectional study:  the HAALSI/AWI-Gen collaborative study conducted in the Agincourt 
sub-district of the Mpumalanga province.  2110 adults 40+ years being monitored by the 
Agincourt health and socio-demographic surveillance system were randomly selected and 
recruited, after giving informed consent, between 2013-2016. Pretested questionnaires were used 
to collect personal, household, socio-demographic, behavioral, dietary, physical activity and self-
reported health status. Anthropometric measurements were also conducted. Multivariable linear 
and logistic regression analyses were used to determine factors associated with serum lipid levels 
and dyslipidemia, respectively. 
Results: Results are presented for 2110 participants in this secondary analysis of which 60.3% 
were women with a mean population age of 58.54 ± 10.91 years. The HIV prevalence was 
16.16% and did not differ substantially between men and women. Factors associated with total 
cholesterol level included age (unstandardized beta [95% CIs] was: 0.02 [0.01, 0.03]; p=0.014), 
male gender (-0.31 [-0.57, -0.05]; p=0.019), diabetes (0.31 [0.01, 0.61]; p=0.039), alcohol 
consumption (0.25 [0.02, 0.48]; p=0.038) and BMI (0.02 [0.01, 0.04]; p=0.030). Factors 
associated with triglycerides included age (0.01 [0.01, 0.03]; p=0.003), male gender (-0.09 [-
0.19, 0.01]; p=0.053), diabetes (0.27 [0.13, 0.40]; p<0.0001), BMI (0.01 [0.01, 0.03]; p=0.044), 
hip circumference (-0.01 [-0.02, -0.01]; p=0.001) and waist circumference (0.01 [0.01, 0.02]; 
p<0.0001). Factors associated with HDL-C level included age (-0.01 [-0.01, 0.01]; p=0.055), 
male gender (-0.14 [-0.26, -0.02]; p=0.018), receiving ART (0.17 (0.04, 0.31); p=0.038), alcohol 
consumption (0.19 [0.07, 0.30]; p=0.002), waist circumference (-0.01 [-0.01, -0.001]; p=0.001) 
and visceral adipose tissue (-0.03 [-0.04, -0.01]; p=0.002). Age (0.02 (0.01, 0.03); p=0.005), 
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male gender (-0.22 (-0.43, -0.01); p=0.044) and waist circumference (0.01 (0.01, 0.02); 
p<0.0001) were all associated with LDL-C levels. Being HIV+ and ART naive was associated 
with a higher risk of dyslipidemia (odds ratio [95% CIs] was 3.79 [1.27, 11.30]; p=0.032) 
compared to HIV negative participants. Other factors associated with dyslipidemia included 
being overweight (1.66 [1.20, 2.30] p=0.002) and obese (OR 1.85 [1.02, 3.35]; p=0.0004) and 
increased waist circumference (OR 1.02 [1.01, 1.03]; p<0.0001). 
Discussion and conclusion: We have demonstrated a high prevalence of HIV in an older 
population of rural South Africa, which mirrors the typical epidemiology of the epidemic in 
southern and eastern African regions. Our data suggest that HIV/ART status mainly influences 
HDL-C levels with ART use associated with higher HDL; and that untreated HIV infection can 
be linked to a greater risk of dyslipidemia. Dyslipidemia in the study population is driven by 
prevailing traditional cardiovascular risk factors such as obesity and diabetes. This data suggests 
that high ART coverage may reduce atherogenic risk and that lifestyle interventions to reduce the 
risk of obesity and diabetes are essential.  
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1.0 CHAPTER 1:  INTRODUCTION 
This chapter gives a brief background to the study by summarizing current knowledge as well as 
gaps in this knowledge. Presented here also is the burden of HIV/AIDS and antiretroviral therapy 
(ART) coverage in sub-Saharan Africa and South Africa. The chapter further describes the 
burden of cardiometabolic diseases as well as risk factors among HIV/AIDS patients who use or 
do not use ART.  
This chapter gives a review of published literature on normal lipid and cholesterol metabolism 
and how HIV and ART independently affect serum lipids. We also summarize factors associated 
with serum lipids and dyslipidemia and their subsequent influence on cardiovascular risk. A brief 
description of the various methods of assessing dyslipidemia is included in this chapter. The 
chapter also includes the statement of the problem addressed by the study and a justification for 
the study. We conclude this chapter with the research question addressed the aim and objectives 
of the study. 
1.1 Background to the study 
Dyslipidemia is associated with an increased risk of cardiometabolic disease (1) among HIV 
infected patients and the general population (2, 3). ART often exacerbates it among people living 
with HIV (PLWH) (4, 5). While sub-Saharan Africa continues to bear a huge burden of 
HIV/AIDS and tuberculosis (6), non-communicable diseases (NCDs) are also on the increase (7). 
The Eastern and Southern Africa regions alone contributed nearly half (46%) of people living 
with HIV (PLWH) globally in 2015 (8).  
Though the number of PLWH is still high (and increasing), AIDS-related mortalities have 
decreased by 45% since the peak in 2005 and new cases are declining globally (8). Similarly the 
national prevalence of HIV in South Africa has declined from 12.2% in 2012 (9) to 11.2% by 
mid-2015 (10). There has also been an observed increase in access and use of antiretroviral 
therapy (ART) with the current global estimate of 54% among PLWH (8). This global situation 
reflects what has been experienced by South Africa, which continues to suffer a huge burden of 
the HIV epidemic (8-10).  
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The increase in ART coverage has led to a decrease in incidence of opportunistic infections and 
resulted in long-term survival among PLWH (11). Urbanization, changing lifestyles and 
changing age and sex structure of most African countries due to the current epidemiological 
transition, has also contributed to a rise in the proportion of older people in the population (12, 
13).  
Disease patterns are gradually shifting from dominantly infectious to non-infectious (or a mix of 
the two) as a major source of morbidity and mortality (2, 14). Thus, a threefold increase in non-
communicable diseases has been observed for low and middle income countries (LMIC) with 
Ghana, Nigeria and South Africa experiencing a rise in prevalence of chronic diseases in the 
midst of a continuing  threat of infectious diseases (1, 12).  
In South Africa, 41% of all deaths were attributed to non-communicable diseases according to 
mortality trends from the second South African National Burden of Disease study (15). 
The prevailing risk factors associated with NCDs include smoking, alcohol consumption, 
obesity, unhealthy diet, inadequate physical activity, psychological factors and dyslipidemia (2, 
7, 16). While the high-income countries have the same prevailing risk factors, there is a decline 
in NCDs compared to sub-Saharan Africa. This is largely due to effective population and 
individual level interventions (1). 
Atherogenic dyslipidemia has been implicated as a cause of cardiovascular diseases (CVDs) in 
both the general population and among PLWH (3). Studies from high-income countries have 
implicated HIV infection itself, the use of ART as well as exposure to the prevailing classical 
CVD risk factors experienced by the general population, as the causes of increased atherogenic 
dyslipidemia among PLWH (17, 18).  
However, comparative population-based epidemiological data on the variations in lipid levels 
and prevalence of dyslipidaemia among PLWH and the general population is scarce in sub-
Saharan Africa (4) as are any in-depth studies on the factors causing dyslipidemia. 
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1.2 Literature review 
1.2.1 Epidemiology 
Globally, PLWH have increased from 33.3 million in 2010 to 36.7 million people in 2015 (8) . 
Sub-Saharan African contributes significantly to the global burden of HIV with South Africa 
having the highest prevalence of HIV (8). The 2015 mid-year prevalence study in South Africa 
reported an estimated overall prevalence of approximately 11.2% (6.19 million PLWH in 2015) 
within the population (10).  Adults aged 15-49 years had a higher estimated HIV prevalence of 
16.6% (10). 
Though the prevalence is still high, South Africa has experienced a 60% reduction in new cases 
of HIV from 2008 to 2012 (9). This can be attributed to effective public health interventions 
including an increase in ART coverage among PLWH from 16.6% to 31.2% (9).   
Globally, HIV-related mortalities are generally decreasing while diseases of lifestyle are 
increasingly becoming a major cause of morbidity and mortality among PLWH (3). Data on 
trends in mortality across Africa are generally scarce. A study in Uganda observed a  sustained 
11 years of decline in the trends of HIV-related mortalities since the introduction of highly active 
antiretroviral therapy in 2004 (11). Similarly, mortality from opportunistic infection among HIV 
patients has declined since the scale-up of ART in 2004 in South Africa (14). 
Globally, NCDs accounted for 63% of deaths (48% due to CVDs) in 2015 and projected to 
increase to 75% by 2030 in the general population (1). In South Africa, it is estimated that 40% 
of all deaths in 2008 were due to NCDs with the leading reported cause being CVD (15). These 
changes result from the ongoing epidemiological and demographic transition across Africa (12, 
13). Life expectancy has generally increased making diseases of lifestyle the major contributor to 
morbidity and mortality. 
PLWH are therefore living longer and experiencing the normal ageing process. This renders 
them prone to the traditional cardiovascular risk factors confronting the general population (3) as 
well as HIV-specific and ART-related mechanisms that appear to increase cardiovascular risk 
(19, 20). 
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1.2.2 Normal cholesterol and lipid metabolism 
Lipid metabolism involves the breakdown and storage of endogenous (produced in liver and 
peripheral tissues) and exogenous (dietary sources absorbed from the gut) fat in the liver (see 
Figure 1.1). The liver synthesises approximately 1g of cholesterol whilst the human diet accounts 
for approximately 400mg daily (21). 
 
 
Figure 1.1: Lipid and cholesterol metabolism (Courtesy: https://www.google.co.za and 
http://www.sgul.ac.uk) 
 
Not only does the liver synthesize cholesterol for export to other cells, but it also removes 
cholesterol from the body by converting it to bile salts in which form it can be eliminated in the 
faeces. Furthermore, the liver synthesizes the various lipoproteins involved in transporting 
cholesterol and other lipids throughout the body (22).  
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Endogenous lipids are derived from lipogenesis (fatty acid and triglyceride synthesis) in the 
liver. In this process, acetyl-coA, an intermediate product of carbohydrate metabolism is 
converted to fatty acids (21). The synthesised fatty acids are then secreted from the liver into the 
bloodstream as very low-density lipoprotein (VLDL), which is formed from triglycerides and 
cholesterol esters.  The VLDL then functions to deliver endogenously derived lipids to peripheral 
tissues (22).  
 
The VLDL is hydrolysed by lipoprotein lipase in the peripheral tissues, particularly skeletal 
muscle and adipose tissue to release free fatty acids and glycerol, with the free fatty acids been 
taken up into the tissue. This hydrolysis of the VLDL particles gives rise to intermediate density 
lipoprotein (IDL). The IDL is then cleared from the circulation by the liver or incorporated into 
LDL. The LDL particles contain a core of cholesterol esters and a smaller amount of 
triglycerides.  
 
The LDL is then used as a source of cholesterol for cells being internalized by hepatic and non-
hepatic tissues. In the liver LDL is converted into bile acids and is secreted into the intestines and 
in the non-hepatic tissues it is used in hormone production, cell membrane synthesis or stored.  
 
The excess LDL in the circulation can also become oxidised and this oxidised LDL is taken up 
by macrophages inducing the formation of foam cells. These cells are the initiators and principal 
components in atherosclerotic plaque formation (21, 22). Most of the dietary cholesterol exists as 
free sterol while 10-15% exists as cholesterol esters. The latter is hydrolysed by cholesterol 
esterase in the gut to release free cholesterol for absorption (21).  
 
The resultant non-esterified cholesterol is then incorporated into bile acid micelles together with 
triglycerides, phospholipids, ionized fatty acids, 2-monoacylglycerol and lysophospholipids (21). 
The mixed micelle thus formed is then transported to the brush border of enterocytes where it is 
absorbed. Within the enterocytes further triglycerides and cholesterol then combine with the 
mixed micelle to form chylomicrons which enter into circulation and travel to peripheral tissues 
(21, 22).   
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In the peripheral tissues, free fatty acids are released from the chylomicrons by lipoprotein lipase 
to be used as energy or converted to triglyceride and stored in adipose tissue. Remnants are then 
used for the formation of VLDL particles in the liver (22). 
 
HDL-C is a key mediator in the reverse cholesterol transport pathway (see Figure 1.2) by 
delivering cholesterol from macrophages in the arterial wall to the liver where it is processed for 
excretion from the body. In this pathway, HDL-C also transports cholesterol from the intestines 
to the liver. Lipid-poor Apo A-1 is secreted by the liver and intestinal cells into the circulation. 
 
Figure 1.2:  Mechanism of reverse cholesterol transport (source: https://www.google.co.za) 
 
The Apo A-1, which makes up 70% of protein in HDL-C, is responsible for the anti-
atherosclerotic properties of HDL-C. Apo A-1 interacts with ABCA1 to develop nascent HDL-
particles, which accumulate more cholesterol from foam cells in the arterial wall.  
 
The nascent and later matured HDL-C thus facilitates efflux of cholesterol from peripheral 
macrophages enabling reverse cholesterol transport (see Figure 1.2). The mature HDL-C delivers 
cholesterol to the liver through either the direct or the indirect pathway (23, 24).  
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The HDL-C interacts with the SR-B1 receptor on the liver via the direct pathway allowing 
delivery of cholesterol to the liver.  The resulting lipid-poor HDL-C particle then re-enters 
circulation where it can repeat the process of reverse cholesterol transport. 
 
In the indirect pathway, HDL-C interacts with the cholesterol ester transfer protein (CETP). This 
CETP protein facilitates the exchange of cholesteryl esters for triglycerides between HDL and 
VLDL or LDL-C particles (25).  The LDL particles may remain in circulation or interact with 
the LDL-receptor on liver cells where LDL particles deposit the cholesterol ester for removal 
(25). 
 
After cholesterol is delivered to the liver by either the direct or the indirect pathway, it is secreted 
into bile and carried to the intestines. The net effect of the reverse cholesterol transport pathway 
is the removal of cholesterol from plaques and the potential reduction of cardiovascular disease 
(23). 
1.2.3 Dyslipidemia 
PLWH often present with deranged lipid profiles due to abnormalities in lipid metabolism (2). 
Current literature on the aetiology of this observation is not clear (26). Several possible theories 
have been put forward to explain this observation. Thus, HIV infection itself and use of ART 
among HIV infected patients have independently been implicated as a cause of changes in lipid 
levels (18, 27, 28).  
This association however, is potentially influenced by many factors that independently can result 
in abnormal serum lipidemia (26). The prevailing traditional risk factors, chronic inflammation 
resulting from HIV and the effect of drug metabolites as well as drug interactions have all been 
implicated as contributors to serum lipidemia (1, 19, 29).  
Several other contributory factors include nutritional deficiencies from HIV infection, 
opportunistic infections, drug-induced cardio-toxicity and prolonged immune suppression (26).  
1.2.4 HIV-associated dyslipidemia  
Before the introduction of HAART, deranged lipid profiles were observed and described among 
HIV infected people (26). Early studies showed that patients infected with HIV type 1 (HIV-1) 
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when compared to uninfected patients had elevated levels of serum triglycerides (TGs) and 
decreased levels of serum total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) 
and high density lipoprotein cholesterol (HDL-C) (18, 26).  
Recent studies in Japan and other high-income countries among HIV-positive patients but 
antiretroviral therapy-naïve with no prior history of ART use confirmed the above observation 
(26, 30). The Japanese study demonstrated that HIV infection and socio-demographic factors 
independently influence serum lipid levels. The study further documented low HDL-C and high 
TGs are the predominant lipid abnormalities among HIV infected patients who were ART naïve 
(26).  
Contrary to the above findings, hospital-based studies from sub-Saharan Africa found a decrease 
in serum LDL-C, HDL-C and triglycerides among HIV positive ART naïve patients compared to 
HIV patients on ART (31, 32). However, these studies did not take into account a wide range of 
confounding variables. 
Possible mechanism: Serum viremia in early HIV-1 infection results in systemic inflammatory 
response and activation of the immune system. Lipoprotein lipase (LPL) and hepatic lipase levels 
decrease resulting in decreased TGs concentration and clearance. Hepatic synthesis of very low-
density lipoprotein-cholesterol (VLDL) increases (33). Triglyceride concentration and clearance 
is reported to correlate strongly with overproduction of interferon-alpha (IFN-α) and other 
inflammatory cytokines such as tissue necrosis factor alpha (TNF-α) (33).  
These pro-inflammatory mediators promote lipid peroxidation, disturb FFA metabolism and 
suppress hormone-mediated lipolysis (33-35). Activity of cholesterol ester transfer protein 
(CETP), which usually transfers cholesterol from HDL-C to apolipoprotein-B, is elevated in 
severe HIV viremia causing elevated TGs. The high activity of CETP in HIV infection however 
results in low HDL-C (19, 27, 29, 33).   
The associated decrease in serum HDL-C levels is often described as a highly atherogenic state 
and thus increases cardiovascular risk (33). The fall in cholesterol levels observed with HIV 
infection may also occur because cholesterol plays a critical role in the replication of HIV-1 (35). 
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1.2.5 ART-associated dyslipidemia 
The current goal in HIV case management is to achieve viral suppression using ARTs (3). Since 
the introduction of ART in the 1990's, prognosis among HIV patients has improved drastically 
(18, 32, 33). This has led to significant improvements in the quality and duration of life of most 
infected patients. 
Associated with these gains however, are clinical and laboratory evidence of a rise in metabolic 
disorders among patients receiving ART (33, 36). The evidence points to the fact that ART is 
associated with lipodystrophy syndrome which is characterized by dyslipidemia, insulin 
resistance, fat redistribution to the visceral adipose tissue depot resulting in central obesity and to 
the nuchal region resulting in typical buffalo hump (cervical pad accumulation of fat) (33, 37). 
Other associated pathologies documented include metabolic bone disease (osteopenia and 
osteoporosis) and lactic acidosis (33). 
Typically, ART associated dyslipidemia is characterized by raised serum triglycerides, total 
cholesterol and low-density lipoprotein (LDL-C), and a decrease in serum high-density 
lipoprotein (HDL-C) (33). Other molecules affected are very low-density lipoproteins (VLDL-C) 
and apolipoprotein B (apoB), both of which tend to be raised in the serum. These changes to the 
serum lipid profile increase cardiovascular risk in PLWH.  
These metabolic changes associated with the use of ART are largely dependent on the drug 
regimen used (30). Nucleotide reverse transcriptase inhibitors (NRTIs) such as stavudine (d4T), 
lamivudine (3TC) and zidovudine (AZT) are reported to account for ART-related toxicity and 
metabolic changes (30). Unfortunately, due to cost, d4T and AZT were largely used across 
Africa as part of the first line regimen since the introduction of ARTs in 2004.  
However, following reports of the severe toxicity and adverse metabolic outcomes, d4T has 
since being withdrawn (38) while AZT is still widely used as part of the first line regimen. Some 
of the protease inhibitors (PIs) such as ritonavir (RTV), lopinavir (LPV) and atazanavir (ATV), 
currently used as second line are also known to cause dyslipidemia (33, 34). 
Current first line regimen recommended by the South African HIV physicians association 
includes a combination of one non-nucleoside reverse transcriptase inhibitor (NNRTI) such as 
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nevirapine (NVP) and efavirenz (EFV) and two suitable nucleotide reverse transcriptase 
inhibitors  (one of which is zidovudine) (36).  
Dyslipidemia among patients on newer antiretroviral agents such as etravirine (NNRTI), 
raltegravir (protease integrase strand transfer inhibitor), maraviroc (CCR5 antagonist), 
apricitabine or elvucitabine (NRTI) and bevirimat (maturation inhibitor) have also been reported 
from high-income countries (39, 40).  
A study in Cape Town, South Africa among HIV patients documented elevated levels of 
triglycerides, LDL-C and TC among patients on ART compared to ART naïve patients. However 
HDL-C levels were lower in both patients on ART and ART-naive patients when compared to 
HIV negative patients (32).  
In comparison, a study in Uganda showed high HDL-C in patients receiving ART, and TC and 
LDL-C levels were also observed to be high (41). Another longitudinal study in Johannesburg, 
South Africa showed that initiation of ART was associated with increased TC, triglycerides, 
LDL-C and HDL-C (38). 
A study from Cameroon, West Africa among HIV patients who had initiated ART within six 
months documented elevated LDL-C and triglyceride levels but decreased HDL-C (31). While 
the studies from Cape Town, Uganda and a longitudinal study in Zimbabwe (42) compared lipid 
levels between ART- naïve patients and patients with a history of ART use, the other studies only 
focused on patients on ART.  
However, a recent meta-analysis of African studies conducted by Dillon et al, (2) demonstrated 
that ART was associated with increased LDL and HDL levels (4) 
Thus, the individual studies from Africa tend to show a positive effect of ART use on TC, LDL 
and triglyceride levels whereas there are some inconsistencies with regard to the effect of ART 
use on HDL levels. 
Since most of these studies in Africa were hospital based and not at the population level,  the 
introduction of  biases is likely substantial. Most of the studies did not have HIV negative 
controls and did not consider a wide range of potential confounding factors. 
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Possible mechanisms: Cunha et al, (2015) described ART-associated dyslipidemia as the result 
of a complex of mechanisms involving aspects of immunological, hormonal, and genetic 
predisposition, as well as direct interactions between ARV metabolites (33). Studies have 
observed that ART impairs the hydrolysis of triglyceride-rich lipoproteins by tissue lipase 
resulting in a reduction in peripheral storage of free fatty acids (FFA).  
The drugs also disrupt normal post-prandial catabolism of FFA (26). Protease inhibitors have 
been reported to inhibit degradation of apolipoprotein B resulting in increased levels in serum 
triglycerides, TC and LDL-C (43).  
Combined PI and NRTI use inhibit preadipocyte maturation and therefore hasten peripheral 
lipoatrophy and cause a rise in triglycerides (43).  
The FRAM study further supported this observation in that d4T and indinavir, a PI were reported 
to be associated with significant decreases in leg subcutaneous adipose tissue but not visceral 
adipose tissue (44).  
1.2.6 Measuring lipids 
A typical lipid profile (full lipogram) measures total cholesterol (TC), triglycerides (TGs), high-
density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) (45). 
The TC is often used for screening purposes, assessing risk, monitoring treatment in cases of 
constraint resources and difficulty in obtaining LDL-C levels. The LDL-C levels however, are 
used for deciding on initiation of anti-lipid therapy (45, 46). 
Lipid profile can be assessed using either serum in laboratory-based assays or via cost-effective 
ways such as point-of-care finger prick testing. For screening and initial diagnosis of 
dyslipidemia in the general population, current guidelines from South Africa recommend 
conducting a full lipogram (TC, HDL-C, LDL-C and TGs) using a finger prick testing (point-of 
care testing) device (46). Lipid profiles for this study were measured using point-of-care testing. 
There are a number of different guidelines used for assessing dyslipidemia and these are mainly 
from Europe (47) and America (45) where populations are predominantly Caucasian. 
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Dyslipidemia for this study is defined using the South African dyslipidemia guidelines consensus 
statement, which was adopted from the European Society of Hypertension (ESH) and European 
Society of Cardiology guidelines (46).  
The cut-offs used are a total cholesterol ≥ 6.21 mmol/L (112 mg/dL), and/or low-density 
lipoprotein cholesterol > 4.1 mmol/L (74 mg/dL), and/or high-density lipoprotein cholesterol < 
1.19 mmol/L (21.42 mg/dL) and/or triglycerides > 2.25 mmol/L (40.5 mg/dL) (46). 
1.2.7 Factors associated with dyslipidemia  
Studies from high-income countries have documented that HIV infection and ART affect lipid 
levels (20). Many other factors modulate lipid levels and are often not measured in these studies 
so it is possible that the association between HIV and lipids is influenced by several other 
dependent covariates.  
However, there is a paucity of data on factors associated with each of the serum lipid fractions – 
taking account of a wide range of confounding factors, including HIV infection and ART use in 
sub-Saharan Africa.  
Some studies have measured a limited number of possible confounding factors in HIV positive 
subjects. Thus, Bekolo et al (2014) documented that viral load, current smoking, and > 2 years 
use of ART were positively correlated with LDL-C while alcohol was rather protective (31). A 
study in South Africa found a positive correlation between age, CD4 lymphocyte count, body 
mass index (BMI) and skin fold thickness, and triglyceride levels (32).  
Studies from Nigeria observed that the WHO stages of HIV infection, and waist circumference, 
were positively correlated with all four molecules of serum lipids (28, 48). Studies in high-
income countries demonstrated that men having sex with men (MSM), smoking, other metabolic 
diseases such as diabetes and regimens of ART were all associated with dyslipidemia (26).  
Some studies have reported an association between moderate-to-vigorous physical activity and 
serum lipids (49, 50). 
An earlier baseline study in the Agincourt population – from which participants were recruited 
for the current study – demonstrated that advanced age, sex, treatment history among HIV-
positive patients and waist-to-hip ratio (WHR) were associated with lipid levels (51). 
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Furthermore, visceral adipose tissue (VAT) and subcutaneous adipose tissue (SCAT) have are 
predictors of serum lipid levels in another black South African population (52, 53).  
However, no studies have investigated the effects of these body fat depots on lipid levels in HIV-
positive subjects in Africa.  A few studies conducted in the United States of America, have 
performed such investigations. These studies showed that decreased leg SCAT and more VAT 
among HIV positive men and women were associated with proatherogenic lipids levels (44, 54). 
The risk of dyslipidemia among HIV positive patients was likely mediated by HIV-associated 
lipoatrophy (54).  
1.2.8 Cardiovascular risk 
HIV/AIDS patients tend to have a higher prevalence of CVDs than the general population (2). 
This is primarily due to the high prevalence of pro-atherogenic lipid levels plus the prevailing 
traditional risk factors for CVDs that are also observed in the general population (51, 55).  
Thus, studies among a cohort of HIV patients in the United Kingdom confirmed the increased 
risk of CVD in this population (5). Further studies among HIV patients in Brazil comparing the 
Framingham, PROCAM and DAD equations for assessing cardiovascular risk reported an 
increased risk among HIV patients than HIV negative controls (56).  
Furthermore, a study applying the atherosclerotic cardiovascular disease (ASCVD) risk score on 
an HIV positive cohort in Gaborone, Botswana reported an increased risk of CVD among HIV 
positive patients compared to an HIV negative population (57). Other cross-sectional studies in 
West Africa found increased risk of CVD among HIV patients compared to HIV negative 
controls (58). These findings were confirmed by a cross-sectional study in a rural South African 
population (59). 
Dyslipidemia causes increased cardiovascular risk in the general population as well. 
Longitudinal studies in the general population have reported increased hazards of cardiac events 
among people with dyslipidemia compared to those without (60). 
Evaluation of cardiovascular risk among individuals without prior history of cardiovascular 
disease showed that high LDL-C and low HDL-C were significantly associated with later 
development of cardiovascular disease (61, 62). 
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1.3 Statement of the problem  
Low and middle-income countries especially in sub-Saharan Africa have the highest global 
burden of HIV/AIDS with South Africa being the single country with the highest prevalence (9). 
There is also an evolving trend of an increasing burden of chronic diseases – including both non-
communicable and infectious conditions – of which pro-atherogenic dyslipidemia among HIV 
infected patients is a major contributor (3). 
Most of the studies on the association of HIV and ART with dyslipidaemia were conducted in 
high-income countries among Caucasians. In such countries, the HIV epidemic is mainly driven 
by special population groups such as men having sex with men, intravenous drug users, the 
increasing transgender population, and high influx of immigrants mainly from SSA (63).   
The distribution of the HIV burden in sub-Saharan Africa, given an essentially heterosexual 
epidemic, is almost equal among males and females with a slight tilt towards females in the 
younger age groups. It is mainly driven by unprotected heterosexual intercourse, multiple sexual 
partners and concurrent sexually transmitted infection.  Mother-to-child transmission (MTCT) 
resulting from inadequate access to treatment and high numbers of uncircumcised males are also 
major drivers of the epidemic in SSA. The voluntary medical male circumcision programme 
implemented in 14 priority countries (including South Africa) in the southern African region (63, 
64) was meant to reduce the transmission of HIV. 
Due to the relative contribution of these different population characteristics and prevailing 
confounding factors, findings from studies in high-income countries cannot be extrapolated to 
represent communities in low and middle-income countries, like those in sub-Saharan Africa.  
Furthermore, large-scale population-based studies on the differential prevalence of dyslipidaemia 
among HIV patients compared to the general population are still lacking in sub-Saharan Africa. 
Also lacking, are studies that include the assessment of a broad array of factors that may 
modulate lipid levels including HIV-status and ART use.  
This poses a constraint to the effective screening of CVD risk among PLWH. It has led to 
increasing calls to the research community to investigate this phenomenon.  
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1.4 Justification for the research 
Current evidence suggests that many demographic, environmental and biological factors 
influence dyslipidemia. Failure to account for these is likely to result in a biased estimate of the 
association between HIV/ART use and dyslipidemia.  
Longitudinal studies that effectively consider time give a clearer picture of this association 
however, population-based epidemiological studies – whether cross-sectional or longitudinal – 
considering a wide range of potential confounding factors can give a useful estimate of the 
association between lipid levels and effector variables. 
Most of the studies in sub-Saharan Africa are hospital-based and have not considered a  range of 
confounding factors which could affect the association between HIV/ART and serum lipid 
levels. This study examines a wide range of socio-demographic, environmental and 
anthropometric risk factors that could confound the association between HIV and ART on serum 
lipid levels. 
Novel to this study is the use of visceral and subcutaneous adipose tissue measures as potential 
confounding factors. Most studies tend to use crude measures of central obesity such as waist 
and/or hip circumference. However, VAT and SCAT as ascertained using ultrasound scans offer 
greater precision to the measure of central obesity (65).  
The study also draws its strength from the Agincourt health and socio-demographic surveillance 
system (HDSS) dataset, which involves a rich longitudinal cohort with in-depth assessment of 
many demographic and environmental factors that are pertinent to our study (66).  
The study will therefore contribute to the growth of knowledge in this evolving field at a 
population level; and offer an assessment of the effect of VAT and SCAT on lipid levels in a 
population with a high prevalence of HIV-infection.  
1.5 Main research question 
What is the effect of HIV infection and ART use on serum lipid levels among adults in 
Agincourt, rural South Africa in 2015? 
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1.6 Study Aim 
To determine the factors, including HIV infection and ART use, associated with lipid levels and 
dyslipidemia among adults in Agincourt, rural South Africa in 2015. 
1.6.1 Study objectives  
1. To describe the socio-demographic characteristics of adults aged 40+ years living in 
Agincourt, rural South Africa in 2015. 
2. To compare lipid levels and prevalence of dyslipidemia between HIV-negative, HIV-positive 
but ART-naive and HIV-positive but ART-exposed adults in Agincourt, South Africa in 2015. 
3. To identify the factors associated with the four lipid species and dyslipidemia among adults in 
Agincourt, South Africa in 2015. 
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2.0 CHAPTER 2: MATERIALS AND METHODS 
This chapter describes the materials and methods used in the primary study. Brief descriptions to 
the study setting, study design and participant characteristics are in this chapter. The chapter 
further describes the data management process and statistical analysis plan employed to arrive at 
the results of this nested study. 
2.1 PRIMARY STUDY 
2.1.1 Background of primary study 
This study is nested in two collaborative studies within the MRC/Wits Rural Public Health and 
Health Transitions Research Unit based in the Agincourt sub-district:  
 The Africa Wits-INDEPTH partnership for Genomic studies on cardiometabolic diseases 
(AWI-Gen) of the Human Heredity and Health in Africa (H3A) Consortium is a 
partnership between the University of the Witwatersrand and the International Network 
for the Demographic Evaluation of Populations and their Health in low and middle-
income countries (INDEPTH) (67).  
 The Health and Aging in Africa: Longitudinal Studies of an INDEPTH Community 
(HAALSI), in Agincourt is a partnership between Harvard University, USA, University 
of the Witwatersrand and the INDEPTH Network (68).  
The HAALSI/AWI-Gen collaboration aims to study the interaction of communicable and non-
communicable diseases and their potential impact on adult health and ageing (69). The AWI-Gen 
study (40-60 years) was a subset of the HAALSI study that included participants of 40+ years. 
The AWI-Gen study in addition included extensive anthropometric measurements while the 
HAALSI study included extensive measurements on cognition and ageing. 
2.1.2 Study setting 
The HAALSI/AWI-Gen collaborative studies were conducted in the MRC/Wits Rural Public 
Health and Health Transitions Research Unit in Agincourt sub-district, Mpumalanga province.  
The Agincourt Health and socio-Demographic Surveillance Site (HDSS) located in northeast 
South Africa and bordered by Mozambique is one of the founding members of the INDEPTH 
network (66).  
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It was established in 1992 and has since been monitoring migrations and health events in an area 
that covers a land mass today of 450km
2
. The population of the area has grown from 57 600 
people in 8,900 households in 20 villages to 90,036 people living in 14,382 households in 27 
villages by the end of 2012(66). The major increase in the population is mainly due to the influx 
of Mozambican immigrants into the area in the wake of the civil war in Mozambique.  
While the study setting has a relatively good representation of educational institutions, the 
quality is rather low with relatively few students progressing past secondary school level. Two 
health centres and six clinics provide public health care services in the study area (66).  
The sub-district has an average HIV prevalence of 19.4% (6). The average prevalence of 
abdominal/central obesity is 46.3% among men and 90.3% among women (51) and HIV and TB 
are the main causes of adult related mortalities – although mortality from non-communicable 
causes is increasing.  
2.1.3 Study design 
Both studies were population-based baseline / cross-sectional studies based on the longitudinal 
cohort of adults monitored by the Agincourt HDSS. 
2.1.4 Study population 
The AWI-Gen study consisted of approximately 2500 adults aged 40-60 years while the 
overlapping HAALSI study consisted of approximately 5 000 adults aged  40+ years all of whom 
lived in the Agincourt sub-district  from 2013 to 2016 when the data collection was carried out. 
Both studies have a major focus on cardiometabolic disease and the biological, behavioural and 
environmental determinants and consequences.  
2.1.5 Sampling 
Both studies used random sampling from the HDSS database to select participants from 
households under surveillance in the study area.  However, samples stratified to reflect an equal 
number of men and women by age group.  
2.1.6 Data collection 
All participants provided written informed consent before any study procedures were performed. 
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Both studies used interview-administered questionnaires to collect information on participants. 
Trained local research assistants administered these questionnaires.  
In addition to socio-demographic characteristics collected in common by both studies, the AWI-
Gen study collected information on visceral and subcutaneous adipose tissue, history of co-
morbidities e.g. diabetes, self-reported ART status, dietary history, physical activity and genetic 
data. The HAALSI study, in addition, collected information on mental state, cognition, 
laboratory assessment of HIV status and point-of-care measurements of lipid and glucose levels. 
Point of care lipids and questionnaire were measured in the field while participants were invited 
to the study site for further anthropometric measures on a different visit day.   
2.1.7 How key variables from the primary study were measured 
2.1.7.1 Height and Weight 
With participants in light clothing and without shoes, height was measured using a height sensor 
with infrared measurement and weight was measured using Genesis Growth Management Scale 
from Patient Focus Africa. A trained research officer carried out both measurements. 
2.1.7.2 Waist and Hip circumference 
The waist circumference of the participant were measured to the nearest 0.5cm between the 
lower margin of the least palpable rib and the iliac crest using a stretch-resistant tape measure 
(SECA) according to the guidelines of the WHO 2008 report on waist circumference and waist-
hip ratio (70). The hip circumferences were measured from the outermost part of the gluteus. 
Body mass index (BMI) and waist-to-hip ratio (WHR) were then derived from these 
measurements using WHO (71) recommended cut-offs. 
2.1.7.3 Visceral and Subcutaneous adipose tissue (VAT and SCAT) 
 
 
A LOGIQ e ultrasound system (GE Healthcare, CT, USA) with a 2-5 MHz 3C-RS curved array 
transducer was used to determine VAT and SCAT thicknesses. USS VAT thickness was defined 
as the distance (cm) from the peritoneum to the vertebral bodies, and USS SCAT thickness was 
defined as the depth (cm) from the skin to the linea alba.  
20 | P a g e  
 
The scan depth was set at 15 cm for the visceral fat measure and 9 cm for the subcutaneous fat 
measure to visualize the relevant anatomical structures. Both measurements were obtained where 
the xyphoid line and the waist circumference met (53, 65). The coefficient of variation for USS 
measurement for the HAALSI/AWI-Gen collaborative studies ranged from 5-8%. 
2.1.7.4 Moderate-to-vigorous physical activity (MVPA) 
The global physical activity questionnaire (GPAQ) was used to assess self-reported physical 
activity (72). The total moderate-vigorous physical activity (MVPA) in minutes per week 
(mins/wk) was calculated from the accumulated occupation, travel-related and leisure time 
physical activity. 
2.1.7.5 Diabetes status 
Diabetes was defined from self-report of ever being diagnosed with diabetes or glucose ≥ 7 
mmol/l in fasting group (defined as > 8 hours), or glucose ≥11.1 mmol/l  in non-fasting (“random 
or casual”) group (73). Individuals with missing fasting information were considered to be not 
fasting.  
2.1.7.6 HIV status 
For prevalence of HIV, we used the results from blood using a protocol of sequential assays. 
Specifically, the Vironostika Uniform 11 (Biomeriuex, France) screening assay was used to 
detect the presence of the virus and in samples that tested positive the Roche Elecys (USA) assay 
(confirmatory) was used to determine the viral load on DBS.  
Contradictory results were resolved using the Siemens Centaur XP (USA) immunoassay, in 
accordance with World Health Organization (WHO) guidelines (74, 75). All individuals who 
consented to the blood collection and testing regardless of prior knowledge of their status were 
subsequently tested. 
2.1.7.7 ART status 
Use of ART assessed by self-report. Results from laboratory confirmation were not immediately 
available at the time of writing this report. 
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2.1.7.8 Lipid profile 
Lipid profiles (non-fasting) were measured using a calibrated point-of-care (POC) device, 
CardioChek® PA silver version by Polymer Technology Systems, Inc. Indianapolis, Indiana, 
USA. 
2.2 SECONDARY DATA ANALYSIS METHODS 
2.2.1 Study design 
This secondary analysis is a population based cross-sectional study nested within the two 
collaborative studies described above. 
2.2.2 Data source 
Both the scientific leadership of the MRC/Wits Rural Public Health and Transitions Research 
Unit and the Sydney Brenner Institute of Molecular Bioscience, University of the Witwatersrand, 
Johannesburg, South Africa, provided data for this secondary analysis. 
2.2.3 Study population 
Adults age 40+ years living in the Agincourt sub-district HDSS coverage area from 2013 to 
2016. 
2.2.4 Study sample 
We merged the two datasets from AWI-Gen and HAALSI to produce a sub-sample of 2 344 
adults aged 40+ years. We then included all participants with data on exposure and outcome of 
interest into this secondary analysis and 2110 individual met this inclusion criterion and was thus 
used for the final analysis.  A retrospective power calculation using a two-sample proportions 
test used to determine the adequacy of this sample.  
The proportion of HIV negative (75.6%) and HIV positive (24.2%) participants with 
dyslipidemia were used for the power calculation. With hypothesis that HIV and ART causes an 
increase in ones risk of dyslipidemia, we sought to determine the power that would detect a 
difference in proportions at an alpha level of 5%. 
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The estimated power to detect an absolute increase of 10% in prevalence of dyslipidemia for our 
sample was almost 100%. We concluded this sample adequately powered to answer our research 
question. 
2.2.5 Selected variables for the secondary analysis 
2.2.5.1 Independent/Exposure variable 
The exposure variables were the HIV status provided by the HAALSI study and ART status as 
provided by the AWI-Gen and HAALSI studies. 
2.2.5.2 Dependent/Outcome variable 
The outcome variables were each molecule of the serum lipid profile: total cholesterol (TC), 
triglycerides (TGs), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein 
cholesterol (LDL-C) 
2.2.5.3 Covariates/Predictor variables 
These selected from variables measured in the combined studies and their selection for use in the 
multivariable regression models and guided by prior knowledge taken from the current literature. 
These included socio-demographic, behavioural and dietary variables, and clinical and 
anthropometric variables, as described below. 
2.2.5.4 Socio-demographic variables 
Data collected for age, sex, and marital status, highest level of education, employment status, 
household wealth asset index and household size (number of individuals living in the household). 
Participants’ ages were categorized into age groups (40-44; 45-54; 55-64; 65+) according to the 
South African National Health and Nutrition Examination Survey categorization (SANHANES) 
(76). 
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2.2.5.5 Behavioural physical activity and dietary variables 
These included alcohol use, smoking history, and average sleep in hours per day and moderate-
to-vigorous physical activity (MVPA). Dietary variables included number of servings of fruits 
and vegetables per day and number of sugar-sweetened beverages (SSB) consumed per day. 
2.2.5.6 Clinical and anthropometric variables 
The main clinical variable measured was diabetes status as a co-morbidity that can influence 
lipid levels. 
Anthropometric variables included weight, height, waist and hip circumference, visceral adipose 
tissue and subcutaneous adipose tissue. Weight and height were used to generated body mass 
index (weight [kg]/height
2 
[m]). BMI was then categorized according to the WHO Expert 
Committee report on physical status into: underweight: <18.5, Normal: 18.5 to < 25, Overweight 
25 to <30, Obese: >= 30 (71). The VAT and SCAT data provided by the AWI-Gen study. 
2.3 Data management and analysis 
2.3.1 Data management 
Relevant variables for these participants extracted and checked for completeness, consistency 
and duplicates. Frequency tables used to check for missing data. Two of the continuous variables 
had more than 20% missing data: subcutaneous adipose tissue, 24.7%; and visceral adipose 
tissue, 24.8%.  
In order to ensure precision and eliminate bias, mean value imputations done for missing data. 
The following variables were selected, based on prior knowledge, as strong correlates of the 
missing variables; age, sex, HIV status, BMI and diabetes. These variables used to replace each 
missing value with the mean of the observed values for that variable. The drawback to this is 
underestimation of the standard deviation and distortion of the estimated association towards 
zero (77).   
We subsequently built our models with the original variables and later on with the imputed 
variables. We then compared the changes in the R-squared value, the direction of association and 
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level of significance. Where the magnitude of change in effect measure (or R-squared of the 
model) and level of significance was not significantly different (<10% change), we maintained 
the model that did not include the imputed data. Where a significant difference was observed, we 
maintained the imputed data in the model. 
The final cleaned dataset containing 2110 participants is used for all data analysis in this study. 
Relevant variables were then calculated e.g. BMI, WHR, high TC, high TGs, low HDL-C, high 
LDL-C and dyslipidemia. 
2.3.2 Generating and re-categorization of key variables 
2.3.2.1 Exposure status 
A combined exposure status was generated based on HIV and ART status. Three mutually 
exclusive categories; HIV negative, HIV positive plus ART use and HIV positive but ART naive 
were generated. 
2.3.2.2 Dyslipidemia  
Dyslipidemia was diagnosed if one or more of the following criteria were met: elevated total 
cholesterol (≥6.21 mmol/L), low HDL (1.19 mmol/L), elevated LDL (>4.1 mmol/L), elevated 
triglycerides (>2.25 mmol/L) (46) and if the subject reported being clinically diagnosed with and 
receiving treatment for high cholesterol. A binary outcome generated using above criteria to 
describe dyslipidemia as "Yes" or "No".    
2.3.3 Statistical analysis 
Both descriptive and inferential statistical analyses conducted in this study. STATA version 13 
(StataCorp LP, Texas USA) was used to perform all the analyses. 
2.3.2.1 Descriptive analysis 
Frequencies were generated using cross-tabulation to describe the categorical characteristics of 
study participants stratified according to sex. Continuous variables are expressed as median 
(inter-quartile range) if skewed and mean ± SD for normally distributed data. Pearson's Chi 
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square (χ2) or Fisher’s exact test used to compare differences in categorical variables between 
groups whilst the t-test used to compare differences in normally distributed continuous variables.  
A non-parametric test, the Wilcoxon–Mann–Whitney U two-sample test (Rank sum test) used 
for comparing gender differences for skewed continuous data. A p < 0.05 considered statistically 
significant. One way ANOVA used to compare differences in mean serum lipid levels across the 
three exposures categories (HIV negative, HIV+ ART+ and HIV+ ART naive). 
 
2.3.2.2 Multivariable linear regression analyses 
Multivariable linear regression models were built for each of the 4 lipid species.  
The outcome variables were normally distributed hence there was no need for transformation to 
normality. In building the linear models, we examined the independent association between the 
exposure (HIV-, HIV+ on ART and HIV+ ART naive) and each of the outcome (LDL-C, HDL-
C, TC and TGs) variables and the relationship of each of the selected predictor variables with 
each of the outcome variables in univariable linear regression analyses.  
A stepwise forward selection method used in building the models. Variables that correlated with 
lipids at p ≤ 0.2 in the univariable linear regression analysis were included in the multivariable 
linear regression analysis.  We also checked for multicollinearity between related variables 
particularly the anthropometric variables using the variance inflation factor (VIF). Variables with 
a VIF greater than 10 dropped from the model.  
Unstandardized beta coefficients with 95% confidence intervals (95% CI) were used to measure 
the magnitude of association and p < 0.05 was considered statistically significant for the final 
model.  For categorical variables with more than two levels, a post estimation test ("testparm") 
was used to examine the overall significance of the said variable in the model and this generates 
a single p-value. 
We used magnitude of R-squared to compare the various models generated, aiming at a higher 
R-squared for the final model. This is because the R-squared gives an idea of the proportion of 
the variance of the dependent variable that is explained by the model.   
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Additionally, Akaike's and Schwarz's Bayesian information criteria (AIC and BIC) post-
estimation test was used to compare the fitted models. The final model had the lowest AIC and 
BIC.  
The Breusch-Pagan/Cook-Weisberg test for homogeneity of variance was used to ensure 
residuals of each of the final models were approximately normally distributed / homoscedastic.  
The final parsimonious model from the linear regression analysis was checked for model 
specifications and for omitted-variables bias using the Ramsey regression specification-error test.  
2.3.2.3 Multivariable logistic regression analyses 
Each of the four lipid fractions were re-categorized into binary outcomes i.e.  Increased TC, 
increased TGs, increased LDL-C and decreased HDL-C. The independent association of 
HIV/ART status with each of these four binary outcomes was determined using univariable 
logistic regression. 
A final binary outcome variable, dyslipidemia was generated by combining each of the four lipid 
molecule categorical variables, as described previously using standard guidelines.  
We initially determined the independent association of each of the selected covariates or 
predictor variables with dyslipidemia in a univariable logistic regression analysis. Variables 
significant at a p<0.2 were then included in a multivariable logistic regression analysis. A 
variance-covariance (robust estimation) approach was used to estimate standard errors in the 
models.  
Multicollinearity was determined by ensuring that the VIF for the variables in the final model 
was less than 10. The Wald test was used to compare significance between the various models 
generated and the final parsimonious model had a higher Wald test. 
As explained for the linear regression models, the categorical variables with more than two 
levels were analysed using a post estimation test to determine the overall significance of the said 
variable in the model and this produced a single p-value. 
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Odds ratios (OR) with 95% confidence interval (95% CI) were used to measure the magnitude of 
association and p < 0.05 was considered statistically significant. The final parsimonious model 
from the logistic regression analysis checked for model specifications goodness of fit test.  
 
2.4 Ethical consideration 
The main AWI-Gen/HAALSI collaborative studies at Agincourt received ethical clearance from 
the University of the Witwatersrand Human Research Ethics Committee (ethics approval 
numbers: M121029 and M110138, respectively). Participants at recruitment signed written 
informed consent before all study procedures. 
Further ethical approval for this secondary analysis, was obtained from the Human Research 
Ethics Committee of the University of the Witwatersrand, Johannesburg. Ethics certificate 
number: M161197. 
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3.0 CHAPTER 3: RESULTS 
This chapter provides detailed results for this study. 
3.1 Socio-demographic characteristics of study participants 
Results of the secondary analysis of 2 110 participants are presented.  
Table 3.1a shows the socio-demographic characteristics of the study participants stratified by 
sex. 
The participants consisted of 838 (39.7%) men and 1 272 (60.3%) women and the mean (± SD) 
age was 58.54 ± 10.91. There was a significant difference in mean (± SD) age among women 
(59.86 ± 11.03) and men (57.67 ± 10.7 years; p < 0.0001). 
The largest groups of the study participants (31.8%) were in the 65+ year's group with more men 
(36.2%) than women (29.0%) in that age group (p < 0.0001). While the 40-44-year-old group 
contributed a smaller number of participants with 11.3% males and 12.5% females.  
 
Over 50% of the participants had some form of formal education from the primary level to 
tertiary level. Of those that had, no form of formal education there were more women (43.8%) 
compared to men (35.8%; p < 0.0001). There was a moderately high employment rate of 72.7%, 
with slightly more men (73.1%) employed compared to women (72.5%) (See Table 3.1a). 
More men were currently married (68.9%) than women (42.2%) who were more likely to be 
widowed (39.6%) when compared to men (10.4%). These demographic differences were highly 
significant (p < 0.0001). 
There was no difference between men and women when it came to household wealth asset index, 
(p = 0.579). A majority of the participants lived in a household composed of seven or more 
people. We observed that fewer women (6.4%) were likely to be living alone compared to men 
(14.0%; p < 0.0001) (Table 3.1a).  
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Table 3.1a Socio-demographic characteristics of adults in Agincourt sub-district in 2015 
  
Women 
(n=1272, 60.3%) 
Men 
(n=838, 37.7%) 
Total 
(N=2110) 
p-value n (%) n (%) N (%) 
Age in years -mean ± SD 59.86 ± 11.03 57.67 ± 10.7 58.54 ± 10.91 < 0.0001 
Age groups in years 
a
      
40-44 168 (13.2) 95 (11.3) 263 (12.5) < 0.0001 
45-54 394 (31.0) 199 (23.7) 593 (28.1) 
 55-64 341 (26.8) 241 (28.8) 582 (27.6) 
 65+ 369 (29.0) 303 (36.2) 672 (31.8) 
 Country of origin     
South Africa 871 (68.5) 614 (73.3) 1 485 (70.4) 0.020 
Mozambique/Other 400 (31.5) 224 (26.7) 624 (29.6) 
 Education category     
No formal education 556 (43.8) 299 (35.8) 855 (40.6) < 0.0001 
Some primary (1-7 years) 421 (33.1) 351 (42.0) 772 (36.7) 
 Some secondary (8-11 years) 137 (10.8) 104 (12.4) 241(11.4) 
 Secondary or more (12+ years) 156 (12.3) 82 (9.8) 238 (11.3) 
 Marital status     
Never married 60 (4.7) 55 (6.6) 115 (5.5) < 0.0001 
Separated / divorced 171 (13.4) 119 (14.2) 290 (13.7) 
 Widowed 504 (39.6) 87 (10.4) 591 (28.0) 
 Currently married 537 (42.2) 577 (68.9) 1 114 (52.8) 
 Employment status      
Employed (part or full time) 922 (72.5) 610 (73.1) 1 532 (72.7) 0.002 
Not working 171 (13.5) 144 (17.2) 315 (15.0) 
 Homemaker 178 (14.0) 81 (9.7) 259 (12.3) 
 Household size 
b
      
Living alone 81 (6.4) 117 (14.0) 198 (9.4) < 0.0001 
Living with one other person 122 (9.6) 81 (9.7) 203 (9.6) 
 Living in 3-6 person household 643 (50.6) 370 (44.2) 1 013 (48.0) 
 Living in 7+ person household 426 (33.5) 270 (32.2) 696 (33.0) 
 Wealth asset index 
c
     
1(Poorest) 262 (20.6) 183 (21.8) 445 (21.1) 0.579 
2 254 (20.0) 169 (20.2) 423 (20.0) 
 3 245 (19.3) 160 (19.1) 405 (19.2) 
 4 261 (20.5) 149 (17.8) 410 (19.4) 
 5 (Wealthiest) 250 (19.7) 177 (21.1) 427 (20.2) 
 aAge groups based on SANHANES and DHS surveys; 
b
Household size: Categorical number of 
individuals living in a household; 
c  
Based on household asset index score in 2009. 
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There were a high proportion of migrants from Mozambique (29.6%) in Agincourt. 
3.2 Behavioural characteristics of study participants 
In Table 3.1b, we summarized results for behavioural, dietary and physical activity of study 
participants. 
Men and women differed significantly by alcohol consumption and smoking history. Thus, 
70.4% of men consumed alcohol compared to 24% of women (p < 0.0001). Close to half, (48%) 
of the men had either previously smoked or were current smokers compared to less than 2% of 
women (1.7%; p < 0.0001). 
Table 3.1b Behavioural, dietary and physical activity profile of adults in Agincourt in 2015 
  
  
Women 
(n=1272, 60.3%) 
Men 
(n=838, 37.7%) 
Total 
(N=2110) 
p-value 
 
Alcohol consumption - n (%) 
 
 
 
 
 
 
 Never 966 (75.9) 248 (29.6) 1 214 (57.5) < 0.0001 
Ever and current 306 (24.1) 590 (70.4) 896 (42.5) 
 
Smoking history - n (%) 
 
 
 
 
 
 
 Never 1 250  (98.3) 433 (51.7) 1 683 (79.8) < 0.0001 
Ever and current 22 (1.7) 405 (48.3) 427 (20.2) 
 Physical activity - median 
(IQR)  
   
Average sleep time (hours per 
night) 
8.86 (5.00-13.71) 9.00 (5.00-14.00) 9.00 (5.00-14.00) 0.575 
Moderate-to-Vigorous 
physical activity (MVPA) 
(minutes/week) 
300 (0-1440) 
 
420 (0-1440) 360 (0-1440) 0.008 
Dietary history - median 
(IQR)  
    Fruit intake (servings per day) 1 (1-3) 1.5 (1-2) 1 (1-5) 0.729 
Vegetable intake (servings per 
day) 
2 (1-14) 2 (1-3) 2 (1-14) 0.865 
Sugar Sweetened  Beverages, 
SSB (number/week) 
1 (0-6) 0.5 (0-2) 1(0-6) 0.888 
 
There was no difference in dietary patterns (servings of fruits; p = 0.729 and vegetables; p = 
0.865 and number of sugar sweets and beverages per week; p = 0.888) between men and women.  
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The median (IQR) average sleep time per day was 9 hours (5-14) and there was no difference 
between men and women (p = 0.575). The median (IQR) moderate-to-vigorous physical activity 
for the study population was 360 (0-1440) minutes per week, and was significantly higher in men 
than women (p = 0.008). 
3.3 Clinical history and anthropometric measurements of study participants 
Diabetes was the metabolic disorder measured in this study as a clinical co-morbidity that can 
influence serum lipids. There was no significant difference in diabetes status between men and 
women (p = 0.804) (Table 3.1c). 
Men and women differed significantly for all the anthropometric measurements obtained in this 
study (Table 3.1c). 
The mean (± SD) waist circumference was 96.14 ± 15.70 cm for women and 89.54 ± 13.83 cm 
for men (p < 0.0001). The hip circumference was 107.58 ± 14.78 cm for women and 96.75 ± 
11.62 cm for men (p < 0.0001). The mean (± SD) BMI in kg/m
2
 for men was 24.73 ± 5.68 and 
for women was 29.74 ± 6.65, and this was statistically different (p < 0.0001). Men had a higher 
mean (± SD) waist-to-hip ratio compared to women (p < 0.0001). Obesity (BMI > 30 kg/m
2
) was 
more common among women than men (p < 0.0001).  
This however was not the same for central obesity using ultrasound measurements of visceral 
and subcutaneous adipose tissue. The mean VAT did not differ between men (5.39 ± 2.87 cm) 
and women (5.09 ± 2.65 cm; p < 0.118), whilst the mean SCAT was higher in women (3.21 ± 
2.21 cm) than in men (2.33 ± 2.46 cm; p < 0.0001) (Table 3.1c). 
 
 
 
 
32 | P a g e  
 
Table 3.1c Clinical and anthropometric characteristics of adults in Agincourt in 2015 
  
  
Women 
(n=1272, 60.3%) 
Men  
(n=838, 37.7%) 
Total 
(N=2110)  p-value 
Clinical history 
    Diabetes - n (%)
 e 
142 (11.3) 97 (11.7) 239 (11.5)  0.804 
Waist and hip measurements 
    Waist circumference (cm) - mean ± 
SD 
96.14 ± 15.70 89.54 ± 13.83 93.53 ± 15.33 <0.0001 
Hip circumference (cm) - mean ± SD 107.58 ± 14.78  96.75 ± 11.62 103.39 ± 14.68 <0.0001 
Waist-to-hip ratio - mean ± SD 0.89 ± 0.08  0.92 ± 0.07 0.91 ± 0.08 <0.0001 
Body mass index (BMI) 
    BMI (kg/m
2
) - mean ± SD 29.74 ± 6.65 24.73 ± 5.68 27.76 ± 6.74 <0.0001 
BMI (kg/m
2
) category - n (%)
 d 
    Underweight 20 (1.6) 80 (9.8) 100 (4.8) <0.0001 
Normal 316 (25.1) 396 (48.3) 712 (34.2)   
Overweight 367 (29.1) 215 (26.2) 582 (28.0)   
Obese 558 (44.3) 129 (15.7) 687 (33.0)   
Ultrasound measures of central 
obesity 
    Visceral adipose tissue (cm) -  
mean ± SD 
5.09 ± 2.65 5.39 ± 2.87 5.22 ± 2.76 0.118 
Subcutaneous adipose tissue (cm) - 
mean ± SD 
 
3.21 ± 2.21  2.33 ± 2.46 2.82 ± 2.37 <0.0001 
VAT:SCAT - mean ± SD 2.59 ± 1.90 5.26 ± 3.94 3.78 ± 3.26 <0.0001 
d
 BMI category (Underweight: <18.5, Normal: 18.5 to < 25, Overweight: 25 to <30, Obese: ≥ 30) 
according to WHO (71); 
e
Diabetes definition: Self reported diabetes diagnosis  OR glucose ≥ 7 
mmol/l  (126 mg/dL) in fasting group (defined as > 8 hours), glucose ≥11.1 mmol/l  (200 mg/dL)  
in non-fasting (“random or casual”) samples (73). Individuals with missing fasting information 
considered to be not fasting. 
 
3.4 Participant characteristics by exposure and outcome (lipids) status 
stratified according to sex 
The HIV prevalence in this population was 15.7%. There was no difference (p = 0.319) in 
prevalence between women (16.4%) and men (14.7%) (see Table 3.2a).  
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Table 3.2a HIV/ART exposure status of men and women in Agincourt in 2015 
HIV/ART 
status 
Women 
n (%) 
Men 
n (%) 
Total 
N (%) 
P-value
 
HIV negative 922 (83.6) 634 (85.3) 1 556 (84.3) 0.319 
HIV+ 
(Combined) 
181 (16.4) 109 (14.7) 290 (15.7)  
 
Concerning lipid measurements, nearly half (43.7%) of the participants had dyslipidemia with no 
observed differences between women and men (p = 0.627; see Table 3.2b). 
Table 3.2b Serum lipid levels of men and women in Agincourt in 2015 
Serum lipids Women 
mean ± SD 
Men 
mean ± SD 
Total 
mean ± SD 
P-value 
 
Total 
Cholesterol 
(mmol/L) 
4.59 ± 1.37 3.76 ± 0.96 4.32 ± 1.30 0.082 
Triglycerides 
(mmol/L) 
1.84 ± 1.17 1.61 ± 0.79 1.77 ± 1.06 0.554 
HDL-C 
(mmol/L) 
1.69 ± 0.65 1.89 ± 0.46 1.76 ± 0.59 0.364 
LDL-C 
(mmol/L) 
2.24 ± 1.16 1.26 ± 0.68 1.89 ± 1.11 0.023 
Dyslipidemia - 
n (%) 
g 
524 (44.2) 329 (43.1) 853 (43.7) 0.627 
g
Dyslipidemia broad definition: Elevated TC (≥6.21 mmol/L), OR Elevated triglycerides (>2.25 
mmol/L), OR Low HDL (<1.19 mmol/L), OR Elevated LDL (>4.1 mmol/L), OR reports ever 
diagnosed with high cholesterol (46). 
 
However, when looking at individual lipid  types, the mean (±SD) total cholesterol for adults in 
Agincourt was 4.32 ± 1.30 mmol/L with marginal differences between men and women 
(p=0.082) (Table 2b). Mean triglyceride (p = 0.554) and HDL-C (0.364) levels did not differ 
between men and women. The mean (±SD) LDL-C for women was 2.24 ± 1.16 mmol/L and that 
for men was 1.89 ± 1.11 mmol/L which was statistically different (p = 0.023). 
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3.5 Lipid levels and prevalence of dyslipidemia according to HIV and ART 
status 
Prevalence and 95% confidence (CI) of dyslipidemia and abnormal levels of each of the four 
molecules of serum lipids by exposure status (HIV/ART status) are present in Table 3.3 below. 
Table 3.3 Levels and prevalence of dyslipidemia with 95%CI by exposure status of adults in 
Agincourt in 2015 
 
 
Lipid levels 
HIV negative 
Mean ± SD 
HIV positive on 
ART 
Mean ± SD 
HIV positive 
ART naïve 
Mean ± SD 
 
Total 
(N = 1712) 
h 
Mean ± SD 
 
 
p-value
 
i
 
Total 
Cholesterol 4.23 ± 1.24 4.14 ± 1.12 3.96 ± 1.09 
 
4.20 ± 1.22 
 
0.091 
Triglycerides 1.76 ± 0.95 1.69 ± 0.79 1.75 ± 0.96 1.75 ± 0.94 0.002 
HDL-C 1.54 ± 0.49 1.71 ± 0.53 1.39 ± 0.49 1.56 ± 0.51 0.453 
LDL-C 2.12 ± 0.99 1.96 ± 0.97 1.83 ± 0.97 2.08 ± 0.98 0.910 
    
  
Prevalence of dyslipidemia (95% CI) p-value 
Dyslipidemia
j 
44.5 [42.0, 47.1] 35.8 [30.0, 42.0] 64.7 [40.4, 83.2] 
 
43.5 [41.1, 45.8] 
 
0.008 
High total 
cholesterol 
k 
5.8 [4.7, 7.2] 4.1 [2.6, 7.8] - 
 
5.5 [4.5, 6.7] 
 
0.324 
High 
triglycerides
 l 
22.1 [20.0, 24.3] 17.2 [13.0, 22.5] 31.3 [13.6, 56.7] 
 
21.5 [19.6, 23.5] 
 
0.145 
High LDL
 m 
3.5 [2.6, 4.7] 2.7 [1.2, 5.9] 6.7 [3.5, 9.0] 3.4 [2.6, 4.5] 0.013 
Low HDL 
n 
26.5 [24.3, 28.9] 20.0 [15.5, 25.5] 47.1 [27.5, 69.8] 25.8[23.8, 27.9] 0.652 
h 
288 participants were excluded from prevalence analysis because they did not have results for all four  
types of the serum lipids. 
i
 One way ANOVA was used to compare differences in mean serum lipid levels across exposure status. 
j 
Dyslipidemia definition: Elevated TC (≥6.21 mmol/L), AND/OR Elevated triglycerides (>2.25 mmol/L), 
AND/OR Low HDL (<1.19 mmol/L), AND/OR Elevated LDL (>4.1 mmol/L), OR reports of ever 
diagnosed with high cholesterol. 
k
Elevated total cholesterol (≥6.21 mmol/L); 
l
Elevated triglycerides (>2.25 mmol/L); 
m
Low HDL (<1.19 
mmol/L); 
n 
Elevated LDL (>4.1 mmol/L) (46). 
 
 
The prevalence of dyslipidemia in the entire population was 43.5% (95% CIs, 41.1, and 45.8) 
(see Table 3.3). Dyslipidemia differed by exposure status (p=0.008) (see Table 3). It was highest 
among HIV+ participants who were ART naïve (64.7% [40.4, 83.2]). There was no difference 
35 | P a g e  
 
for high total cholesterol (p=0.324), high triglycerides (p=0.145) and low HDL-C (p=0.652) (see 
Table 3) across the exposure status.  
However high LDL-C differed across the three exposure groups (p=0.013). Thus, HIV+ 
participants who were ART naïve had the highest prevalence of high LDL-C (6.7% [3.5, 9.0]) 
followed by the HIV negative participants (3.5% [2.6, 4.7]) and HIV + participants on ART had 
the lowest prevalence (2.9% [1.2, 5.9]).  
3.6 Factors associated with serum lipids 
We initially determined the association of each independent variable with each of the four 
species of lipids. We then included all variables with p < 0.2 in the univariable analysis in a 
multivariable linear regression model and the outcomes are shown in Tables 3.4 to 3.7. 
 Factors significant at the multivariable analysis are bolded in the tables with their respective p-
values. Age, sex and HIV/ART status irrespective of the p-value in the univariable analysis were 
included in multivariable analysis. Due to the relatively small numbers of person with HIV+ but 
ART naïve (n=18), a sensitivity analysis was done using the adjusted regression models with this 
group and with this group combined with the HIV+ ART+ group (see Appendix 3). The results 
were similar hence; we present the model with the HIV+ART naive group. However, these 
results should be interpreted with caution due to the small number of subjects in this group. 
3.6.1 Factors associated with total cholesterol (TC) 
At the multivariable level, there were significant associations between the following factors and 
TC: age (p = 0.014), sex (p = 0.019), diabetes (p = 0.039) alcohol consumption (p = 0.038) and 
BMI (p = 0.030) (see Table 3.4). A unit increase in participant’s age was associated with a 0.01 
mmol/L increase in TC, whilst males had a 0.52 mmol/L lower level of TC compared to females. 
Though marginally significant (p = 0.093), a higher level of education was associated with a 
reduction in TC levels (see Table 3.4). 
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Table 3.4 Factors associated with total cholesterol in Agincourt, rural South Africa, 2015 
Covariates Univariable analysis Multivariable analysis 
β-coefficients 
(95%CI) 
p-value β-coefficients 
(95%CI) 
p-value 
Age 0.0146 (0.011, 0.021) < 0.0001 0.024 (0.010, 0.031) 0.014 
Sex     
Female Ref Ref Ref Ref 
Male -0.372 (-0.491, -0.273) < 0.0001 -0.315 (-0.572, -0.051) 0.019 
Exposure status     
HIV negative Ref Ref Ref Ref 
HIV+ ART use -0.092 (-0.265, 0.071) 0.372 0.014 (-0.264, 0.279) 0.684 
HIV+ ART naive -0.264 (-0.851, 0.324)  0.412 (-0.510, 1.329)  
Education Status     
No formal education Ref Ref Ref Ref 
Some primary (1-7 
years) 
-0.133 (-0.266, -0.009) 0.0007 -0.081 (-0.291, 0.135) 0.093 
Some secondary (8-11 
years) 
-0.290 (-0.482, -0.119)  -0.230 (-0.541, 0.074)  
Secondary or more (12+ 
years) 
-0.291 (-0.484, -0.115)  -0.394 (-0.720, 0.075)  
Marital Status     
Currently married Ref Ref Ref Ref 
Never married 0.031 (-0.280, 0.213) 0.0054 0.304 (-0.092, 0.691) 0.289 
Separated/Divorced 0.084 (-0.089, 0.251)  0.195 (-0.080, 0.461)  
Widowed 0.221 (0.091, 0.354)  0.016 (-0.235, 0.255)  
Diabetes mellitus     
No Ref Ref Ref Ref 
Yes 0.173 (-0.021, 0.356) 0.054 0.310 (0.019, 0.614) 0.039 
Alcohol consumption     
Never Ref Ref Ref Ref 
Ever or current -0.150 (-0.262, -0.041) 0.009 0.250 (0.021, 0.480) 0.038 
Smoking History     
Never Ref Ref Ref Ref 
Ever or current -0.344 (-0.481, -0.203) < 0.0001 -0.235 (0.524, 0.055) 0.102 
Body mass index 0.029 (0.023, 0.031) < 0.0001 0.024 (0.018, 0.041) 0.030 
Hip circumference 0.014 (0.010, 0.025) < 0.0001 -0.013 (-0.021, 0.015) 0.160 
VAT:SCAT ratio -0.032 (-0.061, -0.010) 0.011 -0.013 (-0.041, 0.022) 0.649 
 
3.6.2 Factors associated with triglycerides (TGs) 
Table 5 shows results of univariable and multivariable linear regression analyses used to 
determine factors associated with serum TGs among participants.  
Factors associated with serum TGs at the univariable level at p < 0.2 are summarized in Table 
3.5 below.  The HIV status was not independently associated with serum TGs (p = 0.553).  
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The following were significantly associated with serum TG levels in the multivariable model: 
age (p = 0.003), BMI (p = 0.044), diabetes mellitus (p < 0.0001), waist circumference (p < 
0.0001) and hip circumference (p = 0.001) (see Table 3.5). Except for male gender and hip 
circumference, the other factors were positively correlated with TGs with diabetes causing the 
highest increase in serum TGs by 0.27mmol/L (0.27 [0.13, 0.40]; p < 0.0001) (see Table 3.5). 
Table 3.5 Factors associated with triglycerides levels among adults in Agincourt, 2015 (from a 
linear regression analysis) 
Covariates Univariable analysis Multivariable analysis 
β-coefficients (95%CI) P-value β-coefficients (95%CI) p-value 
Age 0.012 (0.010, 0.035) 0.002 0.013 (0.011, 0.035) 0.003 
Sex     
Female Ref Ref Ref Ref 
Male -0.120 (-0.219, -0.041) 0.004 -0.099 (-0.198, 0.010) 0.053 
Exposure status     
HIV- Ref Ref Ref Ref 
HIV+ ART use -0.071 (-0.190, 0.062) 0.553 0.065 (-0.060, 0.194) 0.431 
HIV+ ART naive -0.015 (-0.479, 0.441)  0.213 (-0.264, 0.681)  
Diabetes mellitus     
No Ref Ref Ref Ref 
Yes 0.382 (0.251, 0.515) < 0.0001 0.271 (0.134, 0.405) < 0.0001 
BMI 0.031 (0.023, 0.035) < 0.0001 0.014 (0.010, 0.036) 0.044 
Hip circumference 0.015 (0.012, 0.025) < 0.0001 -0.015 (-0.026, -0.011) 0.001 
Waist 
Circumference 
0.012 (0.010, 0.020) < 0.0001 0.014 (0.012, 0.021) < 0.0001 
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3.6.3 Factors associated with HDL-C 
Factors associated with total HDL-C in both univariable and multivariable linear regression 
models are presented in Table 3.6 below.  
Table 3.6 Factors associated with HDL-C among adults in Agincourt, 2015 
Covariates Univariable analysis Multivariable analysis 
β-coefficients (95%CI) p-value β-coefficients (95%CI) p-value 
Age -0.014 (-0.015, 0.031) 0.171 -0.015 (-0.012, 0.014) 0.055 
Sex     
Female Ref Ref Ref Ref 
Male -0.012 (-0.055, 0.040) 0.697 -0.144 (-0.263, -0.021) 0.018 
Exposure     
HIV negative Ref Ref Ref Ref 
HIV+ ART+ 0.170 (0.101, 0.240) <0.0001 0.172 (0.043, 0.315) 0.038 
HIV+ ART naive -0.152 (-0.391, 0.099)  -0.131 (-0.544, 0.281)  
Smoking habits     
Never Ref Ref Ref Ref 
Ever or Current 0.025 (-0.033, 0.085) 0.132 -0.140 (-0.281, 0.015) 0.058 
Alcohol     
Never Ref Ref Ref Ref 
Ever or Current 0.089 (0.055, 0.145) < 0.0001 0.194 (0.075, 0.314) 0.002 
Fruits -0.019 (-0.045, 0.009) 0.159 -0.031 (-0.109, 0.011) 0.183 
Waist circumference -0.008 (-0.020, -0.001) < 0.0001 -0.014 (-0.020, -0.001) 0.001 
Visceral fat -0.044 (-0.051,-0.025) < 0.0001 -0.031 (-0.044,  -0.010) 0.002 
 
 
At the univariable level, age, sex, HIV exposure status, marital status, alcohol consumption, 
smoking, waist circumference, higher number of fruits servings per day and visceral fat were 
associated with HDL-C levels at p < 0.2 (Table 3.6). Apart from HIV+ participants on ART, and 
alcohol consumption, all the above factors were negatively correlated with serum HDL-C levels. 
However at the multivariable level, sex (p = 0.018), HIV exposure status (p = 0.038), waist 
circumference (p = 0.001), alcohol consumption (p = 0.002) and visceral fat (p = 0.002) 
correlated with serum HDL-C levels (see Table 3.6). Smoking and age were marginally 
associated with HDL-C levels (p = 0.055 and 0.058, respectively). 
3.6.4 Factors associated with LDL-C 
Factors associated with LDL-C as ascertained from linear univariable and multivariable 
regression analyses are summarized in Table 3.7. 
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Table 3.7 Factors associated with LDL-C on a linear multivariable regression analysis 
Covariates Univariable analysis Multivariable analysis 
β-coefficients (95%CI) p-value β-coefficients (95%CI) p-value 
Age 0.013 (0.005, 0.013) < 0.0001 0.024 (0.019,0.035) 0.005 
Sex     
Female Ref Ref Ref Ref 
Male -0.330 (-0.419,-0.229) < 0.0001 -0.221 (-0.431, -0.013) 0.044 
Exposure     
HIV- Ref Ref Ref Ref 
HIV+ART+ -0.151 (-0.294,-0.015) 0.057 -0.079 (-0.312,0.151) 0.486 
HIV+ART naive -0.290 (-0.794,0.216)  0.353 (-0.365,1.071)  
Education     
No formal 
education 
Ref Ref Ref Ref 
Some primary 
(1-7 years) 
-0.085 (-0.180,0.033) 0.021 0.034 (-0.155,0.224) 0.670 
Some secondary 
(8-11 years) 
-0.245 (-0.391,-0.090)  -0.131 (-0.411,0.140)  
Secondary or 
more (12+ years) 
-0.032 (-0.181, 0.125)  -0.021 (-0.305, 0.264)  
Marital Status     
Currently 
married  
Ref Ref Ref Ref 
Never married   -0.121 (-0.334,0.091) 0.003 0.244 (-0.111,0.590) 0.372 
Separated / 
divorced 
0.034 (-0.108,0.169)  0.163 (-0.085,0.393)  
Widowed 0.182 (0.071,0.290)  0.034 (-0.180,0.245)  
Alcohol     
Never Ref Ref Ref Ref 
Ever/Current -0.190 (-0.294,-0.109) < 0.0001 0.121 (-0.080, 0.339) 0.235 
Smoking     
Never Ref Ref Ref Ref 
Ever/Current -0.304 (-0.410, -0.199) < 0.0001 -0.140 (-0.384, 0.112) 0.272 
Waist 
circumference 
0.009 (0.006, 0.013) < 0.0001 0.014 (0.010, 0.029) < 0.0001 
VAT:SCAT 
ratio 
-0.033 (-0.051, -0.014) 0.013 -0.024 (-0.051,0.015) 0.143 
 
A large number of variables were associated with serum LDL levels at p < 0.2 in univariable 
analysis (see Table 3.7). However, after adjusting for potential confounders only age (p = 0.005), 
sex (p = 0.044) and waist circumference (p < 0.0001) were significantly associated with serum 
LDL-C levels. Age and waist circumference were both positively associated with LDL, whilst 
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males had lower LDL levels than females (see Table 3.7). VAT and SCAT dropped from the 
model because they interacted significantly with VAT/SCAT ratio. 
3.7 Factors associated with dyslipidemia 
We focused initially on the independent effect of HIV and ART status on dyslipidemia, 
increased TC, TGs and LDL as well as decreased HDL (see Table 3.8). 
The prevalence of dyslipidemia differed significantly between exposure groups. The HIV+ ART 
naïve had a greater than two fold higher odds of dyslipidemia compared to HIV negative 
participants (OR 2.30 [0.84, 6.21]; p = 0.008). The HIV+ART+ participants had a reduced risk of 
dyslipidemia compared to HIV negative participants (OR 0.69 [0.52, 0.92]; p = 0.009) 
HIV status was not associated with the risk of increased TC or LDL-C (p = 0.269 and p = 0.660, 
respectively) among study participants who were receiving ART.   
The odds of increased TGs was 27% lower among HIV positive participants on ART than HIV 
negative participants, but just missed statistical  significance (0.73 [0.51-1.04]; p = 0.086). The 
risk for high TG was higher in those HIV positive and not receiving ART when compared to 
HIV negative subjects but this risk was not statistically significant (1.60 [0.55-4.64]; p = 0.148). 
HIV+ ART naïve participants had a nearly 2.5 times higher risk of low HDL than HIV negative 
participants (2.46, [0.94-6.43]; p = 0.015). The HIV+ART+ participants had a reduced risk of 
low HDL-C compared to HIV negative participants (OR 0.69 [0.49, 0.97]; p = 0.031). 
In terms of gender effects, men had a significantly lower risk for both high TC (p < 0.0001) and 
high LDL (p=0.005) but had a higher risk of decreased HDL-C (p < 0.0001) compared to women 
(see Table 3.8). There was no difference in risk of dyslipidemia (p = 0.627) and increased 
triglycerides (p = 0.109) between men and women (see Table 3.8). 
 
 
 
 
41 | P a g e  
 
Table 3.8 Independent influence of HIV/ART status and sex on serum lipid levels among adults 
in Agincourt, 2015 
 Odds ratios, OR (95%CI) 
Dyslipidemia
o 
High TC
p 
High TGs
q 
Low HDL-C
r 
High LDL-C
s 
Exposure      
HIV 
negative 
Ref Ref Ref Ref Ref 
HIV+ on 
ART 
0.689
 
(0.521,0.920)** 
0.691 
(0.354,1.339) 
0.732 
(0.511,1.044) 
0.694 
(0.490,0.973)* 
0.764 
(0.325,1.810) 
HIV+ ART 
naïve 
2.301 
(0.842,6.215)** 
- 
- 
1.602 
(0.553,4.644) 
2.460 
(0.940,6.431)* 
1.960 
(0.251,15.271) 
Sex      
Women Ref Ref Ref Ref Ref 
Men 0.965 
(0.790,1.155) 
0.288 
(0.170,0.484)*** 
0.834 
(0.661,1.045) 
1.450 
(1.191,1.791)*** 
0.404 
(0.210,0.760)** 
o
Dyslipidemia definition: Elevated TC (≥6.21 mmol/L), AND/OR Elevated triglycerides (>2.25 
mmol/L), AND/OR Low HDL (<1.19 mmol/L), AND/OR Elevated LDL (>4.1 mmol/L), OR 
reports of ever diagnosed with high cholesterol; 
pElevated total cholesterol (≥6.21 mmol/L); 
q
Elevated triglycerides (>2.25 mmol/L); 
r
Low HDL (<1.19 mmol/L); 
s
Elevated LDL (>4.1 
mmol/L) (46). Level of significance denoted as *p<0.05, **p<0.01, ***p<0.0001 vs reference 
group 
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Serum lipids levels were combined to generate a dichotomous outcome, dyslipidemia that was 
then used as the main outcome variable in univariable (i.e. unadjusted) and multivariate (i.e. 
adjusted) logistic regression analyses. The results of these analyses are presented in Table 3.9 
below. 
 
Table 3.9 Factors associated with dyslipidemia among adults in Agincourt sub-district, 2015 
Factors Unadjusted OR 
(95%CI)
 
p-value Adjusted OR 
(95%CI)
 
p-value 
Age in years 0.990 (0.978, 1.009) 0.318 0.988 (0.965, 1.004) 0.089 
Sex     
Female Ref Ref Ref Ref 
Male 0.960 (0.795, 1.152) 0.627 1.299 (0.981, 1.715) 0.063 
Exposure status     
HIV-negative Ref Ref Ref Ref 
HIV+ ART use 0.689 (0.524, 0.921) 0.009 0.861 (0.646, 1.172) 0.032 
HIV+ ART naïve 2.279 (0.844, 6.210)  3.789 (1.275, 11.302)  
Alcohol consumption     
Never Ref Ref Ref Ref 
Ever/Current 0.761 (0.630, 0.910) 0.003 0.844 (0.652, 1.081) 0.174 
Smoking     
Never Ref Ref Ref Ref 
Ever/Current 0.801 (0.644, 1.001) 0.055 1.054 (0.754, 1.461) 0.784 
Diabetes mellitus     
No                                                            Ref Ref Ref Ref 
Yes 1.914 (1.434, 2.545) < 0.0001 1.665 (1.202, 2.301) 0.002 
Waist circumference 1.034 (1.020, 1.045) < 0.0001 1.021 (1.010, 1.034) < 0.0001 
BMI categories in 
kg/m
2 
1.009 (1.003, 1.071) < 0.0001 0.901 (0.952, 1.055) 0.945 
Underweight Ref Ref Ref Ref 
Normal weight 1.098 (0.681, 1.760) < 0.0001 1.006 (0.573, 1.765) 0.0004 
Overweight 2.174 (1.351, 3.490)  1.851 (1.024, 3.355)  
Obese 2.656 (1.660, 4.255)  1.514 (0.771, 2.940)  
 
 
Factors independently associated with a higher or lower risk of dyslipidemia included male 
gender, exposure status, alcohol use, smoking, diabetes, waist and BMI (Table 3.9).  
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After adjusting for the factors in Table 3.9 above, the following were associated with 
dyslipidemia in the multivariable model: exposure status, diabetes, waist circumference, BMI 
and age (marginally significant).  
Age as a continuous variable was associated with a 2% decreased odds of dyslipidemia, however 
this effect missed statistical significance (p = 0.089). The odds of dyslipidemia among men was 
29% higher than among women and this observation was marginally significant (p = 0.063).  
The subjects who were HIV positive and ART naïve had almost a 4-fold higher risk of 
dyslipidemia than those who were HIV negative. 
The odds of dyslipidemia increased by 2% for every 1 cm increase in waist circumference 
(p<0.0001). Increasing BMI was also associated with an increased risk of dyslipidemia. 
Participants with diabetes as a co-morbidity had a 66% higher risk of dyslipidemia compared to 
participants without diabetes mellitus (OR 1.66 [1.34, 1.71]; p = 0.002). 
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4.0 CHAPTER 4: DISCUSSION AND CONCLUSION 
In this chapter, we present an overview of significant findings from our study with possible 
explanations for these findings. We also compared our findings to similar studies conducted 
globally and in South Africa. 
Due to the relatively small numbers of person with HIV+ but ART naive, a sensitivity analysis 
was done using the adjusted regression models with this group and with this group combined 
with the larger HIV+ART+ group. The results were similar hence in both analyses and therefore 
we present the model with the HIV+ART naive group. We however note that the results 
associated with this group must be interpreted with caution due to the low sample number (n). 
4.1 Overview of study findings 
In this study, we described the socio-demographic characteristics, behaviour, clinical history and 
anthropometry of adults residing in the Agincourt sub-district, rural South Africa between 2013 
and 2015. We also determined differences in mean levels of serum lipids and the prevalence of 
dyslipidemia stratified by sex and HIV/ART status.  
We looked at the individual influence of HIV/ART status on each of the serum lipids, first as 
continuous variables and secondly as binary outcomes. We then examined these associations 
adjusting for potential confounding variables measured in the study. 
The major findings from this large population-based cross-sectional study include a relatively 
high proportion of participants over 65 years old signifying an ageing population; a high 
prevalence of HIV infection, being slightly higher in females; and a high prevalence of 
dyslipidemia across all age-sex groups.  
We also observed various complex associations between persons’ HIV/ART status and the four 
lipid fractions when applying multivariable regression models.  Our findings show that HIV+ 
participants on ART had a lower risk of dyslipidaemia and HIV+ ART naïve were at a higher 
risk of dyslipidemia compared with HIV sero-negative participants. 
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4.2 Basic demographic characteristics of study participants.  
The study population consisted of 2110 adults and was largely an ageing population with a mean 
age of 58.54 ± 10.91. The study participants were predominantly South African with a near 30% 
proportion of immigrants from Mozambique, which shares a border with the study area (66). The 
majority of women in the study area had never attended school while a majority of men had 
attained some form of primary education. This corresponds to previous authors’ findings who 
described quality of education in the study area as poor, with limited progression from primary to 
secondary level (66). Nearly half of the women were married while more than half of men were 
married. There proportion of widowed women was higher than in men. This reflects the lower 
life expectancy of men compared to women – that may partly be because of poorer such due the 
HIV pandemic which prior to the HAART era caused high mortality especially among the male 
population.  
While more men had full time employment, most women were likely to be homemakers. In 
addition to the unavailability of adequate jobs, the level of education is generally low in this age 
group. Wealth was distributed equally across the five key household wealth asset indices and 
there was no difference between men and women. 
4.3 Behavioural risk factors and dietary history of study participants 
Alcohol and smoking are established risk factors for cardiometabolic diseases (7). Higher 
proportions of men either consumed alcohol or were currently drinking alcohol compared to 
women. More than half of study participants had never smoked however, more men were likely 
to have a previous history of smoking or are currently smoking compared to females.  
Previous authors had observed the study area was undergoing a transition to high rates of 
cardiometabolic disease with an increase in the number of cardiovascular risk factors occurring 
over the life course (66). Our findings confirm this increasing burden of risk factors resulting 
from lifestyle changes and the effects of changing economic status and urbanization (4, 51). 
The median (IQR) sleeping hours per night was 9 hours (5-14). This correlated with estimates 
reported by previous studies (16, 79). Some meta-analysis reported sleeping ≤5–6 hours/night is 
associated with higher risk of cardiometabolic diseases (80).  Furthermore, a study in Soweto 
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reported similar sleep duration among older participants and found a protective effect on 
increasing BMI (81).  
However, in the multivariable regression analyses we saw no relationship between sleep duration 
and lipid levels. 
Even though our study population was an ageing one, the median (IQR) MVPA exceeded the 
WHO recommended 300 minutes per week required to achieve additional health benefits and to 
reduce risk of cardiometabolic diseases (82). These finding are similar to findings from a study 
in Soweto, South Africa (81, 83). A recent study in the Agincourt area found a slightly higher 
level of MVPA among study participants than was found in the current study. This finding 
suggests a protective effect against cardiometabolic diseases (51). 
Dietary history was measured by servings of fruits and vegetables per day as well as the 
consumption of sugar-sweetened beverages (SSBs) per week. On average, adults in Agincourt 
have one and two servings of fruits and vegetables per day, respectively. An adult in Agincourt 
consumes at least one can of SSB per day.  
There was no difference in dietary patterns between women and men. Several reviews have 
reported that high intake of dietary fibre (fruits, vegetables and whole grain) lowers total 
cholesterol and LDL-C (84). A study in a South African population made a similar observation 
of a negative correlation between eating fruits and vegetable and serum lipid levels (85).  
The Nutrition Society of South Africa (NSSA) recommends consumption of vegetable and fruits 
daily but the guidelines do not give a recommended number per day (86). However, the 
Agincourt population is eating too little fruit and vegetables per day as international guidelines 
recommend at least 5 portions of fruit and vegetables per day (87).  
4.4 Clinical history and anthropometric characteristics of study participants 
The prevalence of diabetes among study participants was 11.5%, which is a significant increase 
from the 3.0% reported by a previous study conducted in 2011 (51). However, this study 
included subjects less than 40 years-of-age and this might account for the lower prevalence. This 
co-morbidity – diabetes – is one that could contribute to dyslipidemia in the study population.  
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Studies have reported increased dyslipidemia among diabetics. This is attributed to defective 
removal of lipids from the bloodstream and changes in plasma lipoproteins resulting in increased 
triglycerides and decreased HDL-C (88, 89).    
There was a higher prevalence of obesity in women than men and this correlated with previous 
findings in the study area and other South African populations (66, 68). The mean visceral 
adipose tissue was higher in men whilst the mean subcutaneous tissue was higher among women. 
This represents the expected sex distribution of central obesity as documented in the literature 
(90). 
The prevalence of HIV in the study population was slightly higher than the national estimates in 
2012 (9, 10) and a previous study conducted within the same study setting in 2013 (6). Sex 
distribution of HIV prevalence in our study reflects the HIV epidemiology across South Africa 
and sub-Saharan Africa where females than males are affected (9).  
This was similar to the sex distribution observed in a recent study in the Agincourt area (51). 
This distribution is a sharp contrast from high-income countries where the prevalence is high 
among males driven mainly by special population groups such as men having sex with men (91, 
92).    
4.5 Lipid levels and prevalence of dyslipidemia according to gender and HIV 
and ART status 
Our findings showed that women had a higher mean LDL-C and TC compared to males, and this 
correlated with findings from a study in Saudi Arabia (60) that sought to examine gender 
differences in prevalence of dyslipidemia.  
However, we observed no difference in mean triglycerides and HDL-C levels between men and 
women in our study and this differed from who reported higher levels of HDL-C among men 
compared to women (60).  
A study in urban Cape Town observed that males were more likely to have high TGs and low 
HDL-C while women rather had higher LDL-C and TC (32).   
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We observed no difference in the mean levels of TC, LDL-C and HDL-C across the three 
HIV/ART exposure groups. However, subjects who were HIV positive and receiving ART 
reported the lowest mean levels of triglycerides.  
The prevalence of low HDL-C, high triglycerides and high LDL-C was highest between the HIV 
positive and ART naïve group. These findings correlate with many studies conducted across 
Africa (28, 48, 58, 59, and 93) but differ from one previous study that reported low HDL-C (62). 
The use of ART has previously been reported to be associated with high TC, HDL-C, LDL-C 
and triglycerides.  
A longitudinal study of a cohort of HIV+ patients on first line ART in a South African 
population also demonstrated significant increases in levels of all types of lipids after 2 years of 
ART use (38). 
We observed the overall prevalence of dyslipidemia among study participants was 43.7% with 
men having a higher prevalence compared to women. We further observed a higher prevalence 
of dyslipidemia among HIV+ but ART naive participants (64.7 [40.4, 83.2] %) compared to 
HIV+ on ART (35.8 [30.0, 42.0] %) and HIV negative subjects (44.5 [42.0, 47.1] %).  
These findings were similar to those reported in South Africa (32, 51, and 59), East Africa (31, 
41, and 93) and West African (28, 48, and 58). 
4.6 Factors associated with serum lipids: data from multivariable regression 
models 
Age and sex had varied associations with each of the four serum lipid fractions. Age was 
associated with increased levels of TC, triglycerides, LDL-C and a decrease in HDL-C, whilst 
male gender, independent of anthropometric measures, was observed to be negatively correlated 
with all four species of lipids. This is consistent with other studies that reported a higher risk of 
increased TC and higher HDL-C among females (94)  
Age has been reported as one of the non-modifiable risk factors for atherogenic lipid levels (1). 
Though the mechanism is unclear, it has been reported that increasing age is associated with 
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increased production of LDL-C, which occurs in parallel with a decreased clearance from the 
body (94).  
Although age is associated with increasing cholesterol levels this can be countered by 
behavioural or drug therapy, with intervention studies demonstrating that lipid levels can be 
modified with dietary and lifestyle interventions (94).  
Factors associated with TC included level of education, alcohol consumption, diabetes and BMI. 
Our results showed that there was a tendency (p = 0.093) for higher educational level to be 
associated with decreased levels of TC. Studies conducted in America have reported a similar 
effect (95).  
A possible explanation for this could be that educated participants are likely to have a better 
perception of risk, better health seeking behaviour, better compliance with medication and better 
access to information on interventions on modifiable risk factors.  
In our study, we observed that alcohol consumption was associated with increased TC levels and 
that nearly two-thirds of the population consumed alcohol, however we were unable to quantify 
and characterise the drinking patterns.  
Alcohol consumption was also associated with raised HDL levels. Alcohol consumption has 
been reported to cause increases in TC, LDL-C, triglyceride and HDL-C (2). A study among 
alcoholics in America reported elevated levels of all subclasses of HDL-C (96). This is likely 
because alcohol in moderate and high quantities causes an increase in the transport rate of 
apolipoproteins A-1 and A-2 (97).  
Increasing BMI was associated with increases in TC and triglycerides. These associations have 
been reported by previous epidemiological studies (94, 98). The major drawback to these studies 
has been under representation of obese subjects. Our study had a high proportion of obese 
participants and our findings correlate with several case-control and cross-sectional studies (59, 
85, 94, 98). Waist circumference was positively correlated with serum lipids. After adjusting for 
BMI in the models, waist circumference was strongly correlated with increased triglycerides and 
LDL-C and decreased HDL-C. Such associations have previously been reported in a number of 
other studies (81, 94, 99, 100). 
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We also observed that in adjusting for waist and BMI, increased hip circumference was 
associated with decreased serum triglyceride. This is contrary to a study in an Asian population 
(101) but correlates with studies from Australia (102) and Canada (103).  
Hip adipose tissue is reported have a better buffering effect on lipid-excess than abdominal fat. 
This buffering effect is attributed to the number and activity of mitochondria in these adipocytes 
(104, 105). A study corroborated these findings when they observed that women with high hip 
fat were more efficient at storing fat derived from a meal than women with high visceral fat 
(106). 
Precise measures of central obesity such as ultrasound measurements of visceral and 
subcutaneous adipose tissue were novel to our study since previous studies in Africa have not 
made use of these measures. Our findings show that visceral adipose tissue was associated with 
decreased serum HDL-C levels. This is consistent with studies in Caucasian populations, which 
report an association between visceral adipose tissue and dyslipidemia among HIV+ men and 
women (44, 54). 
Tobacco (smoke phase) and its products such as tar has been reported to cause increased 
oxidative stress resulting in lipid peroxidation (resulting in increased LDL-C and decreased 
HDL-C) (107). Consistent with this observation was our finding that smoking tended (p=0.058) 
to be associated with decreased levels of HDL-C.  
We observed that being HIV+ and on ART was independently associated with an increase in 
HDL-C levels. This was largely consistent with findings from studies across sub-Saharan Africa 
that report increased levels of TC, triglycerides, LDL-C and HDL-C in subjects receiving ART 
(4, 38).  
However, our results differ from these studies in that we did not observe higher TC, LDL-C or 
triglyceride levels in subjects receiving ART. The reason for this is not clear. However, we can 
hypothesize that subjects receiving ART are accessing health care facilities more frequently than 
those who are HIV negative or ART naïve.  
They may therefore be receiving better clinical care, especially in the sub-district of Agincourt, 
which is part of a large health and demographic surveillance system.  
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A study in a rural HIV clinic in Limpopo reported better health outcomes with improved access 
to healthcare. Even though this study did not assess dyslipidemia as one of the outcomes, high 
patient retention due to access to healthcare was associated with good treatment outcomes (108). 
In addition, this is an older population and it is feasible that ART therapy may not be as 
atherogenic as in younger subjects. These hypotheses obviously require further investigation.  
Diabetes was associated with increased total cholesterol and triglyceride levels. These findings 
are similar to a study conducted in Cape Town (109) and a recent study in the Agincourt area 
(51). Furthermore, diabetes is a well-known cause of dyslipidemia (88, 110). 
 In our study we have therefore demonstrated the influence of age, sex, waist, hip, BMI, alcohol 
consumption, diabetes and education on the various species of serum lipids.  
We have in this study observed that ART use was associated with increased HDL-C levels whilst 
there was no association with TC, LDL-C and triglyceride levels in the multivariable regression 
models.  
4.7 Factors associated with dyslipidemia 
We initially dichotomised each of the serum lipid species and examined the independent risk of 
dyslipidemia and high levels of TC, triglycerides, LDL-C and low levels of HDL-C in each of 
the three HIV/ART groups. 
Similar to previous studies (31, 32, 51), we observed that HIV positive patients who were ART 
naïve had a greater odds of dyslipidemia, high TGs and LDL-C and low HDL-C when compared 
to HIV negative patients. However, only the risk of low HDL levels was statistically significant.  
 We further noticed that HIV+ART+ participants had a reduced risk of dyslipidemia and of low 
HDL.  
After adjusting for several confounders, we observed that dyslipidemia was associated with age, 
HIV/ART status, diabetes, waist circumference and BMI. Sex was marginally associated with an 
increased risk of dyslipidemia with males having a higher risk than females as observed in other 
studies (5). 
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With or without ART, HIV infection is generally associated with dyslipidemia (18).  In our 
study, HIV+ART naïve participants had a higher risk of dyslipidemia compared to HIV negative 
participants. This has been reported in studies conducted in West Africa (111) South Africa (32) 
and non-African countries (27). This can be explained by the fact that as a population based 
study, most of the HIV+ART naïve may be in their initial phase of high viremia, which is 
associated with abnormal lipid metabolism (112).  
Consistent with other studies, increased BMI and waist circumference, and diabetes were all 
associated with dyslipidemia (111, 112) It is interesting that BMI and waist independently 
affected lipid levels suggesting that they act via different mechanisms. 
4.8 Limitations 
Our study has several limitations. The cross-sectional nature of the study limited our ability to 
establish causal relationships between HIV/ART status and dyslipidemia. We also relied on self-
reported use of ART hence; our estimated association could be biased. We did not ascertain the 
duration and treatment regimen of study participants. The scope of confounding variables did not 
include CD4+ count, viral load and inflammatory markers, which cause metabolic and body 
composition abnormalities (19, 29).  
Furthermore, dietary intake was not studied in detail, and it is known that lipid levels are strongly 
influenced by diet. In addition, the sample number of subjects with HIV who were ART naïve 
was low, limiting our ability to identify significant effects of untreated viremia. The use of lipid 
lowering drugs could also affect our estimate of dyslipidemia and mask the effect of HIV and 
ART on lipid levels. The use of point-of-care lipids is also a limitation for the accurate 
estimation of lipid levels. The HIV+ ART naive group had a small number of subjects and 
therefore interpretation of data from this group should be made with caution. 
4.9 Strengths 
To our knowledge, this is the first large-scale population-based study comparing serum lipid 
levels among HIV negative and HIV positive participants at the population level in sub-Saharan 
Africa. The study, additionally, explored the influence of a more precise measure of central 
obesity (ultrasound measures of VAT and SCAT). This to our knowledge is the first to be used in 
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an Africa population of this size and with a high prevalence of HIV infection. Though not 
exhaustive, we had a wide range of confounding variables to enable us to examine the multiple 
influences on lipid levels. The sample size provided us with adequate power to answer the 
research question.  
4.10 Conclusions 
This population has a high prevalence of HIV among older adults in Agincourt. This HIV 
prevalence mirrors the national prevalence and presents a typical picture of HIV epidemiology in 
eastern and southern African regions. In this population, HIV/ART status mainly influences 
HDL levels with ART use associated with higher HDL and untreated HIV infection linked to 
lower HDL levels and a greater risk of dyslipidemia.  
This cohort has a risk of dyslipidemia driven by prevailing traditional risk factors such as obesity 
and diabetes. With the increasing lifespan of PLWH and associated increase in co-morbidities, 
their long-term impact on screening, prevention, and treatment of dyslipidemia needs to be better 
understood. Health systems must strengthen to embrace these evolving health challenges. 
4.11 Recommendations 
With the advent of ART, more patients are likely to go through the normal ageing process and 
experience more metabolic disorders like dyslipidemia. We therefore recommend a longitudinal 
cohort to evaluate the effects of HIV and ART use on serum lipid levels and associated 
cardiometabolic diseases. The HAALSI/AWI-Gen collaborative studies is timely offers a unique 
platform to study the evolution of long-term cardiometabolic risk in an ageing population with a 
high burden of HIV. 
We also recommend routine screening and treatment of disorders of serum lipids among the HIV 
patients to help decrease the risk of cardiovascular diseases and to increase ART coverage. 
Further research questions should focus on the effects of ART drug regimens, especially newer 
versus older drugs, on lipid levels.  
The strong influence of obesity on lipid levels also suggests that lifestyle interventions should be 
used to reduce the risk of dyslipidemia and the associated cardiometabolic diseases. 
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APPENDIX 3: Sensitivity analyses with the HIV+ ART- group and with the group combined with the 
HIV+ART+ group. 
Table 4: Comparison of adjusted linear regression models for TC in which the HIV+ART- is present as 
an individual group or is combined with the HIV+ART+ group 
Covariates ANALYSIS WITH THE HIV+ ART- 
GROUP 
(Adjusted analysis) 
ANALYSIS WITHOUT THE HIV+ ART- 
GROUP 
(Adjusted analysis) 
β-coefficients (95%CI) P-value β-coefficients 
(95%CI) 
P-value 
Age 0.024 (0.010, 0.031) 0.014 0.018 (0.010, 0.025) 0.016 
Sex     
Female Ref Ref Ref Ref 
Male -0.315 (-0.572, -0.051) 0.019 -0.291 (-0.553, -0.034) 0.030 
Exposure status     
HIV negative Ref Ref Ref Ref 
HIV+ ART use 0.014 (-0.264, 0.279) 0.684 0.021 (-0.253, 0.291) 0.897 
HIV+ ART naive 0.412 (-0.510, 1.329)  - - 
Education Status     
No formal education Ref Ref Ref Ref 
Some primary (1-7 years) -0.081 (-0.291, 0.135) 0.093 -0.090 (-0.310, 0.122) 0.074 
Some secondary (8-11 
years) 
-0.230 (-0.541, 0.074)  -0.241 (-0.552, 0.060)  
Secondary or more (12+ 
years) 
-0.394 (-0.720, 0.075)  -0.412 (-0.742, -0.091)  
Marital Status     
Currently married Ref Ref Ref Ref 
Never married 0.304 (-0.092, 0.691) 0.289 0.291 (-0.091, 0.691) 0.330 
Separated/Divorced 0.195 (-0.080, 0.461)  0.189 (-0.090, 0.455)  
Widowed 0.016 (-0.235, 0.255)  0.015 (-0.243, 0.254)  
Diabetes mellitus     
No Ref Ref Ref Ref 
Yes 0.310 (0.019, 0.614) 0.039 0.310 (0.015, 0.612) 0.040 
Alcohol consumption     
Never Ref Ref Ref Ref 
Ever or current 0.250 (0.021, 0.480) 0.038 0.225 (-0.014, 0.463) 0.063 
Smoking History     
Never Ref Ref Ref Ref 
Ever or current -0.235 (0.524, 0.055) 0.102 -0.234 (-0.513, 0.055) 0.106 
Body mass index 0.024 (0.018, 0.041) 0.030 0.024 (0.015, 0.043) 0.035 
Hip circumference -0.013 (-0.021, 0.015) 0.160 -0.013 (-0.024, 0.027) 0.167 
VAT:SCAT ratio -0.013 (-0.041, 0.022) 0.649 -0.015 (-0.041, 0.025) 0.636 
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Table 5: Comparison of adjusted linear regression models for TGs in which the HIV+ART- is present as 
an individual group or is combined with the HIV+ART+ group 
Covariates ANALYSIS WITH THE HIV+ ART- 
GROUP 
(Adjusted analysis) 
ANALYSIS WITHOUT THE HIV+ 
ART- GROUP 
(Adjusted analysis) 
β-coefficients (95%CI) P-value β-coefficients (95%CI) P-value 
Age 0.013 (0.011, 0.035) 0.003 0.013 (0.010, 0.026) 0.003 
Sex     
Female Ref Ref Ref Ref 
Male -0.099 (-0.198, 0.010) 0.053 -0.103 (-0.190, 0.016) 0.061 
Exposure status     
HIV- Ref Ref Ref Ref 
HIV+ ART use 0.065 (-0.060, 0.194) 0.431 0.066 (-0.060, 0.195) 0.306 
HIV+ ART naive 0.213 (-0.264, 0.681)  - - 
Diabetes mellitus     
No Ref Ref Ref Ref 
Yes 0.271 (0.134, 0.405) < 0.0001 0.273 (0.130, 0.415) < 0.0001 
BMI 0.014 (0.010, 0.036) 0.044 0.012 (-0.019, 0.025) 0.067 
Hip circumference -0.015 (-0.026, -0.011) 0.001 -0.009 (-0.080, -0.010)  0.002 
Waist Circumference 0.014 (0.012, 0.021) < 0.0001 0.021 (0.010, 0.026) < 0.0001 
 
 
Table 6: Comparison of adjusted linear regression models for HDL in which the HIV+ART- is present as 
an individual group or is combined with the HIV+ART+ group 
Covariates ANALYSIS WITH THE HIV+ ART- 
GROUP 
(Adjusted analysis) 
ANALYSIS WITHOUT THE HIV+ 
ART- GROUP 
(Adjusted analysis) 
β-coefficients (95%CI) P-value β-coefficients (95%CI) P-value 
Age -0.015 (-0.012, 0.014) 0.055 0.012 (-0.021, 0.018) 0.059 
Sex     
Female Ref Ref Ref Ref 
Male -0.144 (-0.263, -0.021) 0.018 -0.152 (-0.271, -0.036) 0.013 
Exposure     
HIV negative Ref Ref Ref Ref 
HIV+ ART+ 0.172 (0.043, 0.315) 0.038 0.171 (0.035, 0.302) 0.016 
HIV+ ART naive -0.131 (-0.544, 0.281)  - - 
Smoking habits     
Never Ref Ref Ref Ref 
Ever or Current -0.140 (-0.281, 0.015) 0.058 -0.144 (-0.291, -0.015) 0.050 
Alcohol     
Never Ref Ref Ref Ref 
Ever or Current 0.194 (0.075, 0.314) 0.002 0.191 (0.074, 0.325) 0.002 
Fruits -0.031 (-0.109, 0.011) 0.183 -0.031 (-0.080, 0.024) 0.248 
Waist circumference -0.014 (-0.020, -0.001) 0.001 -0.040 (-0.107, -0.010) 0.008 
Visceral fat -0.031 (-0.044,  -0.010) 0.002 -0.032 (-0.056, -0.010) 0.002 
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Table 7: Comparison of adjusted linear regression models for LDL in which the HIV+ART- is present as 
an individual group or is combined with the HIV+ART+ group 
Covariates ANALYSIS WITH THE HIV+ ART- 
GROUP 
(Adjusted analysis) 
ANALYSIS WITHOUT THE HIV+ 
ART- GROUP 
(Adjusted analysis) 
β-coefficients (95%CI) P-value β-coefficients (95%CI) P-value 
Age 0.024 (0.019,0.035) 0.005 0.023 (0.010,0.034) < 0.0001 
Sex     
Female Ref Ref Ref Ref 
Male -0.221 (-0.431, -0.013) 0.044 -0.240 (-0.475, 0.015) 0.051 
Exposure     
HIV- Ref Ref Ref Ref 
HIV+ART+ -0.079 (-0.312,0.151) 0.486 -0.020 (-0.261, 0.263) 0.576 
HIV+ART naive 0.353 (-0.365,1.071)  - - 
Education     
No formal education Ref Ref Ref Ref 
Some primary (1-7 
years) 
0.034 (-0.155,0.224) 0.670 0.024 (-0.171, 0.206) 0.688 
Some secondary (8-
11 years) 
-0.131 (-0.411,0.140)  -0.140 (-0.420, 0.135)  
Secondary or more 
(12+ years) 
-0.021 (-0.305, 0.264)  -0.061 (-0.357, 0.220)  
Marital Status     
Currently married  Ref Ref Ref Ref 
Never married   0.244 (-0.111,0.590) 0.372 0.230 (-0.134, 0.580) 0.416 
Separated / divorced 0.163 (-0.085,0.393)  0.161 (-0.080, 0.394)  
Widowed 0.034 (-0.180,0.245)  0.032 (-0.180, 0.244)  
Alcohol     
Never Ref Ref Ref Ref 
Ever/Current 0.121 (-0.080, 0.339) 0.235 0.055 (-0.190, 0.295) 0.678 
Smoking     
Never Ref Ref Ref Ref 
Ever/Current -0.140 (-0.384, 0.112) 0.272 -0.070 (-0.371, 0.205) 0.591 
Waist 
circumference 
0.014 (0.010, 0.029) < 0.0001 0.010 (0.009, 0.075) 0.003 
VAT:SCAT ratio -0.024 (-0.051,0.015) 0.143 -0.010 (-0.040, 0.025) 0.684 
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Table 8: Independent influence of HIV/ART status and sex on serum lipid levels among adults in 
Agincourt, 2015 
Exposure Odds ratios, OR [95%CI] 
p - value 
Dyslipidemia
 
High TC
 
High TGs
 
Low HDL-C
 
High LDL-C
 
With HIV+ART- 
HIV negative Ref Ref Ref Ref Ref 
HIV+ on ART 0.689
 
[0.521,0.920]
 
p = 0.011
 
0.691 
[0.354,1.339] 
p = 0.269 
0.732 
[0.511,1.044] 
p = 0.086 
0.694 
[0.490,0.973] 
p = 0.031 
0.764 
[0.325,1.810] 
p = 0.541 
HIV+ ART naïve 2.301 
[0.842,6.215] 
p = 0.105 
- 
 
1.602 
 [0.553,4.644] 
p = 0.385 
2.460 
 [0.940,6.431] 
p = 0.056 
1.960 
[0.251,15.271] 
p = 0.519 
Without HIV+ART- 
HIV negative Ref Ref Ref Ref Ref 
HIV+ on ART 0.694  
[0.523, 0.925] 
p = 0.011 
0.689  
[0.354, 1.345] 
p = 0.246 
0.733  
[0.511, 1.047]  
p = 0.086 
0.694  
[0.491, 0.976] 
p = 0.031 
0.765  
[0.324, 1.812] 
p = 0.541 
HIV+ ART naïve - - - - - 
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Table 9: Comparison of adjusted logistic regression models for dyslipidemia in which the HIV+ART- is 
present as an individual group or is combined with the HIV+ART+ group 
Factors ANALYSIS WITH THE HIV+ ART- 
GROUP 
ANALYSIS WITHOUT THE HIV+ 
ART- GROUP 
Adjusted OR 
(95%CI)
 
P-value Adjusted OR 
(95%CI)
 
P-value 
Age in years 0.988 (0.965, 1.004) 0.089 0.990 (0.980, 1.005) 0.156 
Sex     
Female Ref Ref Ref Ref 
Male 1.299 (0.981, 1.715) 0.063 1.291 (0.980, 1.705) 0.065 
Exposure status     
HIV-negative Ref Ref Ref Ref 
HIV+ ART use 0.861 (0.646, 1.172) 0.032 0.860 (0.631, 0.970) 0.035 
HIV+ ART naïve 3.789 (1.275, 11.302)    
Alcohol consumption     
Never Ref Ref Ref Ref 
Ever/Current 0.844 (0.652, 1.081) 0.174 0.832 (0.652, 1.085) 0.169 
Smoking     
Never Ref Ref Ref Ref 
Ever/Current 1.054 (0.754, 1.461) 0.784 1.080 (0.781, 1.505) 0.638 
Diabetes mellitus     
No                                                            Ref Ref Ref Ref 
Yes 1.665 (1.202, 2.301) 0.002 1.642 (1.191, 2.290) 0.003 
Waist circumference 1.021 (1.010, 1.034) < 0.0001 1.024 (1.010, 1.045) < 0.0001 
BMI categories in kg/m
2 0.901 (0.952, 1.055) 0.945   
Underweight Ref Ref Ref Ref 
Normal weight 1.006 (0.573, 1.765) 0.0004 1.020 (0.581, 1.805) 0.0004 
Overweight 1.851 (1.024, 3.355)  1.860 (1.025, 3.390)  
Obese 1.514 (0.771, 2.940)  1.494 (0.760, 2.936)  
 
 
 
 
 
 
